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Abstract			The	 purpose	 of	 this	 project	 was	 to	 develop	 novel	 pharmacological	 tools	 against	Inositol	Monophosphatase	(IMPase)	and	gain	new	insights	into	the	Calbindin-IMPase	interaction.	IMPase	is	an	enzyme	that	has	been	of	significant	therapeutic	interest	since	the	 development	 of	 the	 inositol	 depletion	 hypothesis	 of	 lithium’s	 efficacy	 in	 the	treatment	of	bipolar	disorder.	More	recent	studies	have	implicated	IMPase	inhibition	in	 the	 induction	 of	 autophagy	 and	 the	 clearance	 of	 peptides	 involved	 in	 the	pathogenesis	 of	 neurodegenerative	 diseases.	 Despite	 this	 there	 is	 a	 lack	 of	 specific	inhibitors	 and	 those	 that	 have	 been	 developed	 lack	 favorable	 physiochemical	properties	 to	 explore	 specific	 IMPase	 inhibition	 in	 vivo.	 My	 aim	 was	 to	 find	 novel	inhibiters	and	binding	chemical	 fragments	 that	could	 later	be	developed	 into	potent	specific	 inhibitors	 of	 IMPase	 that	would	 allow	 for	 the	 specific	 evaluation	 of	 IMPase	inhibition	in	vivo.	To	achieve	this,	two	approaches	were	tried:	first	a	crystallographic	fragment	soaking	screen	was	used	to	identify	novel	binding	sites	and	chemical	matter.	This	 resulted	 in	 the	 discovery	 of	 a	 novel	 fragment	 binding	 site	 at	 the	 homodimer	interface	and	mutagenesis	at	this	site	inhibited	IMPase	activity,	indicating	that	the	site	could	 be	 therapeutically	 relevant.	 The	 second	 approach	 was	 to	 screen	 a	 specially	curated	 isothiazolone	 library	 based	 on	 the	 previously	 identified	 covalent	 inhibitor	Ebselen.	Here	I	identified	a	new	class	of	isothiazolone	inhibitors	of	IMPase.		The	calcium	binding	protein	Calbindin-D28k	can	allosterically	modulate	IMPase,	this	results	 in	 the	 increase	 in	 the	 catalytic	 activity	 of	 IMPase.	 I	 aimed	 to	 explore	 this	interaction	 by	 fusing	 the	 proteins	 using	 a	 flexible	 amino	 acid	 linker.	 The	 resulting	complexes	 had	 activity	 in	 excess	 of	 that	 of	 the	 wild	 type	 IMPase,	 confirming	 that	Calbindin-D28k	activated	IMPase.	Low	resolution	structural	analysis	using	small	angle	X-ray	scattering	(SAXS)	revealed	a	V-shaped	IMPase-calbindin	complex	which	was	in	contrast	 to	 the	more	 linear	shape	predicted	by	computational	docking	models.	Here	we	also	obtained	 the	 first	crystal	structure	of	Calbindin-D28k.	This	crystal	 structure	gave	the	 first	direct	visualization	of	 the	calcium	binding	sites	of	 the	protein	and	 is	a	better	model	of	Calbindin-D28k	in	solution	than	the	previous	NMR	structure.		
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Introduction  
		
1.1	Phosphatidylinositol	signaling	cascade 	The	Phosphatidylinositol	(PI)	cascade	is	one	of	the	most	ubiquitous	cell	signaling	pathways	in	intracellular	signaling.	It	involves	the	creation	of	the	phosphorylated	sugar	molecule	Inositol	1,4,5-triphosphate	(IP3).	IP3	is	produced	by	the	hydrolytic	decapitation	 of	 the	 hydrophilic	 head	 of	 phosphatidylinositol	 4,5-bisphosphate	(PIP2).	PIP2	is	a	phospholipid	found	in	the	inner	leaflet	of	the	cell	membrane.	The	hydrolysis	of	PIP2	is	catalyzed	by	Phospholipase	C	(PLC)	activated	downstream	of	G-protein	 coupled	 receptors	 (GPCR)	 which	 is	 the	 most	 common	 route	 of	 PLC	activation.	 There	 are	 multiple	 isoforms	 of	 PLC.	 PLC-γ	 is	 activated	 by	 protein-tyrosine	kinases	due	to	this	PLC	isoform	containing	a	Src	Homology	2	domain.	When	PIP2	 is	hydrolyzed	 two	signaling	molecules	are	produced:	 IP3	and	diacylglycerol	(DAG).	DAG	remains	in	the	cell	membrane	and	activates	protein	kinase	C	(PKC).	In	contrast,	IP3	is	highly	soluble	and	can	diffuse	through	the	cytosol	where	it	binds	to	receptors	inducing	the	release	of	calcium	from	intracellular	sources,	in	particular,	the	endoplasmic	reticulum	(Figure	1)	(Majerus,	1992;	Streb	et	al.,	1983;	Furuichi	et	
al.,	 1989;	 Newton,	 1995).	 IP3	 is	 recycled	 back	 to	 free	 inositol	 by	 a	 series	 of	dephosphorylation	steps	catalyzed	by	enzymes	such	as	Inositol-1,4	bisphosphate	1-phosphatase	 (IPP)	 and	 inositol	monophosphatase	 (IMPase).	 Free	 inositol	 is	 then	utilised	in	the	re-synthesis	of	PIP2	(Gani	et	al.,	1993;	Harwood,	2005).		
Calcium	levels	in	the	cell	cytosol	are	maintained	at	low	levels	(cytoplasmic	levels	are	approximately	 100nM	 whilst	 extracellular	 concentrations	 are	 much	 higher	 at	
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approximately	 1mM)	 by	 the	 action	 of	 calcium	 pumps.	 There	 are	 two	 families	 of	calcium	 ATPases;	 plasma	 membrane	 calcium	 ATPases	 (PMCA	 1-4)	 that	 pump	calcium	out	of	the	cell	and	sarco-	or	endoplasmic	reticulum	calcium	ATPases	(SERCA	1-3)	that	pump	calcium	into	intracellular	stores.	Calcium	is	an	important	signaling	molecule	and	an	increase	in	cytosolic	levels	causes	activation	of		target	proteins	such	as	phosphatases	and	kinases.	Many	functions	are	regulated	by	increases	in	cytosolic	calcium	concentration,	 these	 include	but	are	not	 limited	to	 the	cell	cycle,	granule	secretion	 (exocytosis),	 cell	 contraction,	 apoptosis,	 cell	 adhesion,	 migration	and	transcription	(Berridge,	1993).	 	 
 
	
Figure	1.	An	 illustration	of	 the	PI	signaling	cascade.	GPCR	activation	causes	 the	hydrolysis	
PIP2	by	PLC,		IP3	defuses	through	the	cytosol	and	triggers	the	release	of	calcium	by	binding	to	
receptors	on	the	surface	of	intracellular	calcium	stores	such	as	the	ER.	DAG	remains	in	the	
inner	leaflet	of	the	cell	membrane	after	the	hydrolysis	of	PIP2	and	activates	PKC.	PKC	is	also	
regulated	by	calcium.				
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1.2	IMPase:	Structure	and	function	
IMPase	is	a	highly	conserved	enzyme	found	across	groups	at	the	highest	taxonomic	ranks.	 It	 is	a	metallo-phosphodiesterase	enzyme	that	 requires	2	or	3	magnesium	ions	 for	 its	catalytic	activity	and	 is	 inhibited	by	 ions	such	as	calcium.	 IMPase	 is	a	soluble	 cytosolic	 protein	 that	 assembles	 into	 a	 homodimer	 with	 a	 large	 dimer	interface.	 It	 exhibits	 an	 αβαβα	 structural	 topology	 with	 two	 active	 sites	 per	homodimer	(Figure	2)	(Bone,	Springer,	and	Atack.,	1992).	The	resulting	protein	is	
extremely	 stable	 with	 a	 high	 melting	 temperature	 (Tm),	 for	 example,	H.	 sapiens	IMPase	possesses	a	Tm	of	79°C	(Kraft	et	al.,	2018).		
Mammalian	 IMPase	 exists	 in	 2	 isoforms,	 IMPase1	 and	 IMPase2,	 encoded	 by	 the	
impa1	and	impa2	genes	respectively.	IMPase1	consists	of	a	277	amino	acid	primary	structure	 whilst	 IMPase2	 contains	 an	 extra	 11	 amino	 acids	 on	 the	 N-terminus.		These	extra	residues	do	not	form	any	secondary	structural	elements	and	have	been	suggested	to	be	a	signal	peptide	element.	Excluding	the	extra	N-terminal	region	of	IMPase2,	 the	proteins	share	54%	sequence	 identity.	Structurally	 the	proteins	are	
Figure	2.	A)	A	ribbon	illustration	of	IMPase	with	only	one	chain	of	the	dimer	shown.		The	
secondary	structural	topology	is	shown	with	α-helices	in	red	and	β-sheets	in	turquoise.	B)	
The	IMPase	homodimer.	The	individual	chains	are	depicted	in	different	colours:	one	red	
and	one	orange.	It	can	be	seen	that	both	chains	have	a	similar	polarity	but	the	monomers	
are	not	parallel	as	they	have	a	slight	rotation	relative	to	one	another.	Reference	for	figure	
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homologous,	having	the	same	structural	topology,	with	all	cations	and	ligands	in	the	active	site	positioned	at	the	same	locations	(Arai	et	al.,	2007).	There	is,	however,	a	significant	 difference	 in	 the	 activity	 of	 the	 IMPase	 isoforms.	 	 IMPase2	 has	 lower	activity	than	IMPase1	and	is	also	less	sensitive	to	inhibition	by	lithium	(Ohnishi	et	
al.,	 2014).	 Both	 isoforms	 are	 expressed	 in	 the	 brain	 with	 lower	 expression	 of	IMPase2	 except	 in	 the	 visual	 cortex	 and	 the	 mid-hind	 brain	 when	 compared	 to	IMPase1.	Outside	of	the	central	nervous	system	(CNS)	IMPase2	is	expressed	at	much	higher	levels	than	IMPase1	and	in	some	cases	exclusively	(Ohnishi	et	al.,	2007).		
IMPase	 belongs	 to	 a	 large	 superfamily	 of	 structurally	 related	phosphomonoesterases	 that	 are	 inhibited	 by	 lithium.	 IMPase	 displays	 broad	substrate	specificity	and	can	hydrolyze	many	other	phosphate	monoesters	such	as	those	 in	 β–glycerophosphate,	 adenosine-2'-monophosphate	 and	 p-nitrophenyl	phosphate	 as	 well	 as	 other	 inositol	 monophosphate	 isoforms,	 inositol	 4-monophosphate	and	meso	inositol	5-phosphate	(Ganzhorn	and	Chanal,	1990;	Leech	
et	al.,	1993;	Cole	and	Gani,	1994;	Fauroux	and	Freeman,	2009;	Ackermann	et	al.,	1987).	In	the	following	section	I	will	focus	on	Myo-inositol	1-monophosphate	(IP1)	as	a	substrate	for	IMPase.	
1.2.1	Mechanism	of	action	of	IMPase		
IMPase	requires	magnesium	for	its	catalytic	activity	at	concentrations	of	between	0.5	–	5mM	in	vitro.	Concentrations	of	magnesium	above	5mM	result	in	an	inhibitory	effect	on	IMPase	activity,	suggesting	that	the	release	of	magnesium	from	the	active	site	may	be	a	part	of	 the	catalytic	cycle	of	 IMPase	(Hallcher	and	Sherman,	1980).	There	is	inconclusive	evidence	regarding	how	many	magnesium	ions	are	involved	in	the	catalytic	mechanism,	and	indeed,	the	mechanism	of	catalysis	itself.	There	are	
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three	magnesium	binding	sites	in	the	active	site	of	IMPase;	two	high	affinity	and	one	low	affinity	magnesium	binding	site.	There	are	two	suggested	catalytic	mechanisms	for	IMPase	based	on	the	magnesium	binding	properties;	a	3-metal	mechanism	and	a	2-metal	mechanism	(Pollack	et	al.,	1994;	Lu	et	al.,	2012;	Gill	et	al.,	2005).	Both	mechanisms	function	through	nucleophilic	attack	in	a	similar	way	to	the	mechanism	of	fructose	1,6-bisphosphate	(Johnson	et	al.,	2001).	Glu70	and	Thr95	coordinate	the	first	Mg	magnesium	 and	 the	 second	magnesium	 ion	 is	 bound	 to	 three	 aspartate	residues	 (Asp90,	 93	 and	 220).	 These	make	 up	 the	 2	 highest	 affinity	magnesium	binding	sites.	Glu70	coordinates	the	third	magnesium	ion	and	this	makes	the	only	coordinating	 interaction	 between	 the	 ion	 and	 the	 protein,	 forming	 the	 weakest	magnesium	 binding	 site.	 Both	 proposed	 mechanisms	 use	 the	 activation	 of	 a	nucleophilic	water	molecule	to	catalyse	the	hydrolysis	of	the	IP1	substrate	(Singh	et	
al.,	2012).						
1.3	IMPase	therapeutic	interest		
IMPase	has	been	of	therapeutic	interest	since	it	was	hypothesised	to	be	the	putative	target	of	lithium	therapy	in	the	treatment	of	bipolar	in	the	1980s	(Berridge,	Downes,	and	Hanley,	1982).	More	recently,	it	has	been	demonstrated	that	the	inhibition	of	IMPase	can	stimulate	autophagy	and	attempts	are	ongoing	to	determine	if	this	can	be	exploited	therapeutically	in	neurodegenerative	diseases	(Sarkar	et	al.,	2005).	
1.3.1	Bipolar	Disorder	and	the	inositol	depletion	hypothesis	
Bipolar	 disorder	 is	 a	 psychotic	 disorder	 that	 is	 characterized	 by	 periods	 of	depression	 and	 mania.	 People	 with	 bipolar	 disorder	 are	 often	 diagnosed	 with	depression	in	the	first	instance;	this	is	because	the	characteristic	that	distinguishes	
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bipolar	disorder	from	major	depression	is	the	occurrence	of	mania,	which	can	occur	infrequently.	Initially	referred	to	as	manic	depression,	bipolar	disorder	belongs	to	a	class	of	psychiatric	disorders	known	as	affective	disorders	(mood	disorders).	The	depressive	episodes	of	bipolar	disorder	are	characterized	by	a	low	mood,	a	feeling	of	 low	 self-worth	 and	 patients	 may	 stop	 washing	 and	 feel	 lethargic.	 Depressive	episodes	can	 lead	to	suicidal	 thoughts	and	self-harm.	These	symptoms	occur	at	a	higher	frequency	in	bipolar	disorder	than	in	major	depression	alone.			Mania	 is	 the	 distinguishing	 characteristic	 that	 separates	 bipolar	 disorder	 from	major	depression.	Manic	episodes	are	characterized	by	an	elevated	mood	that	may	be	described	as	euphoric.	Whilst	in	a	manic	phase,	patients	may	require	less	sleep,	often	make	poorly	thought	out	decisions	with	little	regard	to	the	consequences	and	be	 irritable.	 Mania	 in	 severe	 cases	 can	 be	 accompanied	 by	 psychosis	 (American	Psychiatric	Association,	2013).	People	experiencing	mania	often	do	not	seek	medical	intervention	and	may	not	report	it,	leading	to	a	misdiagnosis	of	major	depression	(Hirschfeld,	Lewis,	and	Vornik,	2003).		
Lithium	has	been	used	in	the	management	of	bipolar	disorder	for	almost	100	years	(Cade,	 1949;	 Hammond,	 1871)	 and	 remains	 one	 of	 the	 most	 widely	 used	 and	effective	treatments	(Shorter	2009).	Lithium	is	one	of	the	few	drugs	for	which	there	is	evidence	of	its	use	resulting	in	a	reduction	in	suicidal	thoughts	(Lewitzka	et	al.,	2015).	Lithium,	a	small	cation,	results	in	a	wide	polypharmacology	that	has	made	it	difficult	 to	 determine	 an	 exact	 mechanism	 of	 its	 therapeutic	 action.	 Many	hypotheses	exist	with	varying	amounts	of	evidence	for	each.	In	the	1970’s	studies	
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demonstrated	 that	 lithium	 treatment	 reduces	 inositol	 levels	 in	 the	 brains	 of	mammals	(Allison	and	Stewart,	1971).	This	decrease	in	inositol	levels	was	mirrored	by	an	increase	of	IP1.		It	was	later	shown	that	lithium	inhibits	the	activity	of	inositol	monophosphatase	(Allison	et	al.,	1976;	Sherman	et	al.,	1985).	These	observations	led	to	the	formation	of	the	inositol	depletion	hypothesis	of	lithium’s	efficacy	for	the	treatment	 of	 bipolar	 disorder	 (Berridge,	 Downes,	 and	 Hanley,	 1982).	 This	hypothesis	 suggests	 that	 the	 reduction	 in	 free	 inositol	 levels,	 observed	 following	treatment	with	lithium,	is	a	direct	result	of	the	inhibition	of	IMPase	and	leads	to	the	attenuation	of	IP	signalling.		PIP2	is	not	able	be	re-synthesized	due	to	a	lack	of	free	inositol.	This	inositol	depletion	affect	is	confounded	in	the	brain	due	to	the	slow	rate	at	which	inositol	enters	the	CNS,	compared	to	the	periphery.	Inhibition	of	IMPase	by	lithium	also	inhibits	the	de	novo	synthesis	of	inositol	from	glucose	6-phosphate,	as	the	last	step	requires	IMPase	(Figure	3)	(Barkai,	1981;	Calker	and	Belmaker,	2000).		
No	 specific	 inhibitor	 of	 IMPase	 has	 been	 found	 that	 is	 effective	 in	 vivo.	 The	development	of	a	specific	inhibitor	of	IMPase	would	allow	for	the	direct	evaluation	of	the	inositol	depletion	hypothesis.		
	
	
Figure	3.	Inhibition	of	IMPase	results	in	the	attenuation	of	both	de	novo	synthesis	of	inositol	
from	glucose-6-phosphate	via	Inositol	synthase	(Ino-1)	and	the	recycling	of	inositol	from	the	
Phosphatidylinositol	signaling	cascade	and	other	inositol	isoforms.	IMPase	is	ideally	placed	
as	 a	 target	 for	 the	 attenuation	 of	 inositol	 signaling	 as	 its	 inhibition	 prevents	 inositol	
production	from	multiple	pathways.	Multiple	inositol	polyphosphate	phosphatase	(MInsPP).	
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1.3.2	Autophagy,	Neurodegeneration	and	IMPase	inhibition			
Autophagy	 is	 the	 process	 by	 which	 a	 cell	 removes,	 disassembles	 and	 recycles	damaged	 or	 unwanted	 cellular	 components	 such	 as	 organelle	 and	 protein	aggregates.	The	process	begins	with	the	formation	of	a	membrane	in	which	cellular	waste	 resides	 in	 the	 lumen.	 This	 autophagosome	 then	 fuses	 with	 lysosomes	 (a	membrane	 bound	 organelle	 that	 contains	 hydrolytic	 enzymes)	 to	 form	 a	autolysosome	 in	 which	 the	 constituent	 biomolecules	 within	 are	 broken	 down	(Klionsky	and	Emr,	2000).	Many	neurodegenerative	diseases	are	characterized	by	the	 formation	 of	 protein	 aggregates	 in	 the	 brain.	 These	 proteins	 such	 as	 tau,	 α-synuclein	 and	 huntingtin	 are	 all	 substrates	 of	 the	 autophagic	 system	 (Ross	 and	Poirier,	 2004).	 Therefore,	 stimulating	 autophagy	 and	 the	 removal	 of	 pathogenic	protein	 aggregates	 could	 be	 a	 useful	 therapeutic	 approach	 for	 treating	neurodegenerative	 diseases	 such	 as	 Parkinson’s	 and	 Huntington’s	 disease.	Intracellular	levels	of	both	inositol	and	IP3	negatively	regulate	autophagy	(Criollo	et	
al.,	 2007).	A	 range	of	drugs	 that	 reduce	 intracellular	 levels	 of	 inositol	 have	been	shown	 to	 induce	 and	 upregulate	 autophagy.	 These	 include	 lithium,	 L690-330,	valproic	acid	and	carbamazepine	(Fleming	et	al.,	2011;	Williams	et	al.,	2002).	With	the	 addition	 of	 inositol,	 the	 autophagy-inducing	 action	 of	 these	 drugs	 can	 be	reversed.	 Specific	 inhibition	 of	 IMPase	 by	 L690-330	 resulted	 in	 the	 reduction	 of	pathogenic	peptides	and	protected	against	cell	death	 in	vitro	(Sarkar	et	al.,	2005;	Motoi	 et	 al.,	 2014).	 Down	 regulation	 of	 autophagy	 has	 been	 linked	 to	 a	 wide	spectrum	of	neurodegenerative	diseases,	therefore,	the	stimulation	of	autophagy	by	
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the	 inhibition	of	 IMPase	may	provide	a	 therapeutic	 strategy	 for	 the	 treatment	of	neurodegenerative	diseases	(Shintani	and	Klionsky,	2004).	
1.4	IMPase	Inhibitors	
1.4.1	Lithium		
Lithium	 inhibits	 IMPase	 via	 an	 uncompetitive	 mechanism.	 	 IMPase	 requires	magnesium	for	its	activity.		Lithium	causes	displacement	of	a	magnesium	ion	in	the	active	 site	 of	 IMPase	 and	 inhibits	 the	 release	 of	 the	phosphate	 from	 the	 enzyme	product	 complex.	 Purified	 IMPase	 is	 inhibited	 by	 lithium	 with	 a	 half	 maximal	inhibition	(IC50)	seen	at	a	concentration	of	approximately	0.8mM	(Gani	et	al.,	1993;	Hallcher	 and	 Sherman,	 1980).	 The	 inhibitory	mechanism	 of	 lithium	 requires	 the	presence	of	the	substrate	in	order	to	generate	the	inhibited	lithium-IMPase-product	complex.		Therefore,		the	higher	the	substrate	concentration,	the	greater	the	degree	of	enzyme	inhibition	seen	(Leech	et	al.,	1993).					
1.4.1	L-690,330		
In	 the	1990s,	 the	pharmaceutical	company	Merck	produced	a	series	of	 inhibitors	based	 on	 the	 substrate	 of	 IMPase.	 Design	 of	 drugs	 based	 on	 the	 substrate	 or	transition	state	analogue	is	a	common	strategy	in	drug	discovery.	These	‘substrate	mimetics’	are	typically	competitive	reversible	inhibitors	that	function	by	competing	with	the	substrate	for	the	proteins	active	site.	Merck’s	approach	was	to	synthesis	methylenebisphosphonic	acid	derivatives	of	IP1	that	were	non-hydrolysable	(Baker	
et	al.,	1990).	The	resulting	compound	‘L-690,330’	was	a	potent	inhibitor	of	IMPase	(IC50	0.2μM)	(Figure	4)	(Atack	et	al.,	1993).		
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The	 active	 site	 of	 IMPase	 is	 larger	 than	 that	 required	 to	 accommodate	 the	 IP1	substrate.	 L-690,330	 contains	 an	 additional	 phosphate	 compared	 to	 the	 IP1	
substrate.	This	 extra	phosphate	 forms	 further	 interactions	with	 residues	Trp219	and	Asp220.	IP1	is	a	very	soluble,	highly	polar	substrate	and	the	active	site	of	IMPase	reflects	these	properties	as	does	as	the	substrate	mimetic	L-690,330.	Hydrophilic	drug	molecules	lack	cell	and	CNS	penetration.	IMPase	is	a	cytosolic	protein	that	has	its	therapeutic	region	in	the	CNS	for	the	treatment	of	bipolar	disorder.	Therefore					L-690,330	 lacks	 the	 physicochemical	 properties	 necessary	 for	 it	 to	 be	 a	 good	inhibitor	in	vivo	and	consequently	is	not	of	therapeutic	use.	Attempts	were	made	to	produce	 a	 tetrapivaloyloxymethyl	 ester	 prodrug	 that	would	 be	 less	 charged	 and	therefore	more	cell	permeable.		The	prodrug	would	then	be	metabolised	inside	the	cell	to	the	active	compound	L-690,330,	however	these	compounds	later	failed	in	in	
vivo	studies	due	to	solubility	issues	(Atack	et	al.,	1994).		
	
Figure	4.	The	structure	of	IP1,	the	substrate	of	IMPase,	and	L-690,330	the	
substrate	mimetic	produced	by	the	pharmaceutical	company	Merck.			
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1.4.2	Ebselen	
A	screen	of	the	national	institute	of	health	(NIH)	clinical	collection	revealed	ebselen	to	 be	 an	 inhibitor	 of	 IMPase	 (Singh	 et	 al.,	 2013).	 The	NIH	 clinical	 collection	 is	 a	fragment	 library	made	up	 of	 drugs	 that	 have	 failed	 clinical	 trials	 for	 their	 initial	intended	therapeutic	use	but	have	a	good	safety	profile.	As	there	is	human	safety	data	 already	 available	 for	 these	 compounds,	 they	 can	be	 developed	 cheaper	 and	faster	than	novel	compounds.	This	process	is	known	as	drug	repurposing	and	has	become	 more	 popular	 in	 recent	 years.	 Ebselen	 is	 a	 synthetic	 organoselenium	drug	that	was	 initially	developed	 as	 an	 antioxidant	drug	 that	mimics	 glutathione	peroxidase.	 The	 initial	 therapeutic	 application	 was	 to	 use	 ebselen’s	 anti-inflammatory,	 anti-oxidant	 and	 cytoprotective	 properties	 to	 provide	 a	neuroprotective	effect	 in	stroke	patients	 (Schewe,	1995;	Yamaguchi	et	al.,	1998).	Clinical	trials	determined	that	ebselen	was	a	safe	drug,	despite	the	fact	that	ebselen	contains	 selenium	which	has	known	 toxicity	 issues	 (REF).	Studies	 that	examined		the	metabolism	of	ebselen	determined	that	it	is	metabolised	into	three	products	and	negligible	free	selenium	is	released	(REF).		Ebselen	 inhibits	 IMPase	 non-competitively	 and	 non-reversibly	 (REF).	 Ebselen	contains	 an	 isoselenazolone	 ring	 that	 has	 similar	 activity	 to	 an	 isothiazolone.	Isothiazolones	 contain	 a	 sulphur	 instead	 of	 selenium.	 Isothiazolone	 containing	compounds	are	often	 identified	as	 “hits”	 in	compound	screens	 in	drug	discovery.	Isothiazolones	 and	 isoselenazolones	 are	 reactive,	 having	 the	 ability	 to	 covalently	bind	 to	 cysteine	 residues	 of	 target	 proteins.	 Therefore,	 isothiazolones	 and	isoselenazolones	are	classed	as	pan	assay	interference	compounds	(PAINS)	(Baell	
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and	Nissink,	2018).	In	this	thesis	I	will	be	exploring	the	isothiazolone	reactive	group	in	an	attempt	to	identify	novel	IMPase	inhibitors	(Figure	5).				Ebselen	has	an	 IC50	of	 approximately	1.5μM	with	 respect	 to	 IMPase	 (Singh	et	al.,	2013).	 Ebselen	 exhibited	 IMPase	 inhibition	 ex	 vivo	 and	 mimics	 lithium	 in	behavioural	experiments	tests	in	mice	displaying	symptoms	of	mania	(ref).	Due	to	the	 reactivity	 of	 the	 isoselenazolone	 ring	 in	 ebselen	 and	 its	 small	 size,	 ebselen	possesses	intrinsic	polypharmacology.	The	translation	of	any	potential	therapeutic	efficacy	of	ebselen	to	inhibition	of	a	single	target	protein	is	therefore	difficult.						
		
1.5	The	Calbindin-IMPase	Interaction	
In	 2002	 it	 was	 reported	 that	 calbindin-D28k	 binds	 to	 and	 activates	 IMPase	(Berggard,	Szczepankiewicz,	et	al.,	2002).	The	interaction	was	identified	by	affinity	chromatography	using	calbindin-D28k	immobilized	on	magnetic	beads	and	phage-
Figure	5.	The	isothiazolone	reactive	group	and	the	IMPase	
inhibitor	Ebselen		
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display	peptides	 from	a	random	12	 long	polypeptides	 library.	This	approach	was	used	 to	 attempt	 to	 explore	 the	 calcium	 sensing	 function	 of	 calbindin-D28k.	 One	peptide	with	 homology	 to	 IMPase	was	 highly	 retained	 in	 the	 column.	 Calbindin-D28k	 was	 found	 to	 increase	 IMPase	 activity	 by	 up	 to	 250-fold,	 surprisingly	 in	conditions	 that	 were	 unfavourable	 for	 IMPase	 activity.	 The	 interaction	 and	activating	 effect	 of	 calbindin-D28k	 on	 IMPase	 occur	 in	 both	 the	 absence	 and	presence	of	calcium,	suggesting	that	calbindin-D28k	is	not	acting	as	a	calcium	sensor	in	 this	 interaction.	 The	 interaction	 between	 IMPase	 and	 calbindin-D28k	 has	 a	dissociation	constant	(Kd)	of	0.9	μM.	In	silico	modelling	of	the	interaction	indicated	that	 Lys59	 and	Lys61	of	 IMPase	 along	with	Asp24	 and	Asp26	of	 calbindin-D28k	were	 critical	 residues	 involved	 in	 this	 interaction.	 Mutagenesis	 of	 these	 resides	confirmed	that	they	(all	of	them?)	are	critical	for	the	activating	effect	of	calbindin-D28k	 on	 IMPase	 (Figure	 6)	 (Levi	 et	 al.,	 2013).	 Using	 this	 information,	 small	competitive	 peptide	 interaction	 inhibitors	 were	 designed	 that	 were	 able	 to	attenuate	the	activating	effect	of	calbindin-D28k	on	IMPase.									
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1.5.1	Calbindin-D28k	structure	and	function		
Calbindin-D28k	is	a	calcium	buffering	protein	that	is	present	in	high	concentrations	in	 the	 CNS	 and	 absorptive	 epithelia.	 In	 absorptive	 epithelia,	 calbindin-D28k	expression	is	under	the	control	of	a	vitamin	D	dependent	expression	system,	whilst	in	 the	 CNS	 calbindin-D28k	 expression	 is	 vitamin	 D	 independent	 (Clemens	 et	 al.,	1989;	Arnold	 and	Heintz,	 1997).	 Calcium	 signalling	 is	 central	 in	 cell	 biology	 and	therefore	its	cellular	concentration	is	tightly	regulated.	Calbindin-D28k	is	a	calcium	buffering	 protein	 but	 it	 also	 acts	 as	 a	 calcium	 sensing	 protein	 (Schmidt,	 2012).	Calbindin-D28k	undergoes	small	conformational	changes	upon	calcium	binding	that	initiate	the	binding	of	target	proteins	to	Calbindin-D28k.	Calbindin-D28k	is	a	30kDa	
Figure	6.	A)	The	in	silico	docking	model	of	the	Calbindin-IMPase	complex.	IMPase	in	green	
and	blue	and	Calbindin-D28k	in	yellow	and	lavender.	B)	The	peptide	fragment	of	IMPase	
that	was	identified	as	the	calbindin-D28K	ligand	is	coloured	red.			
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protein	composed	of	6	EF-hand	motifs	with	a	primary	structure	of	261	amino	acids	(Kojetin	 et	 al.,	2006).	 EF-hand	motifs	 possess	 helix–loop–helix	 topology	 and	 are	common	structural	domains	found	in	calcium-binding	proteins.	Loop	structures	in	these	motifs	form	the	calcium	binding	sites	in	calcium-binding	proteins.	Each	of	the	EF-hand	motifs	is	held	together	in	a	single	globular	fold	(Figure	7)	via	hydrophobic	interactions	between	each	motif.	This	structure	is	maintained	in	both	the	calcium	loaded	and	apo	forms.	Calbindin-D28k	has	four	calcium	binding	sites	in	the	loops	of	EF-hand	1,	3,	4	and	5	(Akerfeldt	et	al.,	1996).		DOESN’T	THIS	SECTION	NEED	TO	BE	BEFORE	THE	SECTION	ABOVE???	
1.6	Introduction	to	Biomolecular	Crystallography	
Biomolecular	crystallography	is	a	technique	that	enables	scientists	to	obtain	close	to	atomic	resolution	structure	of	biological	macromolecules.	In	order	for	a	structure	to	be	resolved,	the	molecule	of	interest	must	be	arranged	in	a	regular	lattice	to	form	
Figure	7.	A	ribbon	representation	of	a	nuclear	magnetic	resonance	(NMR)model	of	
calcium	bound	Calbindin-D28k,	with	its	calculated	surface	shown	in	red.	It	can	be	
observed	that	the	protein	forms	a	single	domain	protein	and	has	a	kidney	bean-
shaped	structure.	
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a	 crystal.	 This	 is	 frequently	 the	 rate-limiting	 step	 in	 structural	 determination	 by	bimolecular	crystallography.	The	determination	of	a	crystal	structure	begins	with	the	collection	of	diffraction	data.		Crystals	are	exposed	to	a	beam	of	X-rays	(neutrons	or	electrons	can	also	be	used)	and	diffraction	data	collected.	This	data	is	then	scaled	and	 merged	 and	 phases	 of	 data	 are	 estimated	 by	 imposition	 of	 a	 previously	identified	 model	 or	 are	 obtained	 experimentally.	 The	 model	 generated	 is	 then	refined	against	the	data	to	produce	a	final	structure.			
1.6.1	Protein	crystallisation	
In	order	to	obtain	an	X-ray	crystal	structure	of	a	protein	the	first	step	is	to	crystallise	the	protein	of	 interest.	Currently,	 there	 is	no	precise	method	of	predicting	which	conditions	are	required	for	a	protein	to	form	a	crystal.	Therefore,	a	trial	and	error	approach	is	often	used,	screening	multiple	conditions	in	order	to	identify	those	most	suitable	for	crystallisation.	Crystallisation	experiments	require	a	sample	of	highly	purified	 protein	 at	 high	 concentrations	 (frequently	 in	 excess	 of	 1	 mg/ml).	Precipitants	are	then	added	to	the	protein	solution	and	water	removed	by	diffusion	over	 time	 to	 create	 a	 supersaturated	 sample.	 In	 conditions	 favourable	 to	crystallisation,	 crystals	will	 eventually	 grow	 from	 the	metastable	 supersaturated	solution.		In	conditions	unsuitable	for	crystallisation	the	protein	will	precipitate,	or	phase	separation	may	occur.	It	is	often	the	case	that	the	first	crystal	obtained	from	a	 screen	may	 not	 diffract	well	 or	may	 be	 too	 small.	 In	 such	 circumstances,	 it	 is	necessary	 to	 optimize	 the	 crystallisation	 conditions.	 Changing	 pH	 or	 precipitant	concentration	may	enable	an	experimentally	viable	crystal	to	be	obtained	that	will	diffract	well.	
	The	 most	 common	 method	 of	 growing	 crystals	 (and	 the	 method	 used	
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experimentally	 in	 this	 dissertation)	 is	 a	 technique	 known	 as	 vapour	 diffusion.	Protein	solution	is	mixed	with	a	precipitant	solution	at	defined	ratios	and	kept	in	close	proximity	to	a	reservoir	of	the	precipitant	solution	in	a	closed	system.	Water	from	 the	 protein	 drop	 then	 diffuses	 from	 the	 protein	 drop	 into	 the	 precipitant	reservoir,	 resulting	 in	 a	 progressive	 increase	 in	 the	 precipitant	 and	 protein	concentration	within	the	drop	(McPherson	and	Gavira,	2014).	
After	crystals	are	acquired,	they	are	harvested	on	specially	designed	loops	and	cryo-cooled	in	liquid	nitrogen.	The	crystal	cooling	serves	multiple	purposes,	depending	on	 future	 experimental	 requirements.	 Advantages	 of	 crystal	 cooling	 include;	 a	reduction	of	the	effects	of	radiation	damage,	reduction	in	crystal	movement	during	data	 collection	 and	 to	 help	 prevent	 the	 crystal	 from	 drying	 out.	 Unlike	 small	molecule	 crystals,	 protein	 crystals	 contain	 a	 high	 percentage	 of	 solvent	 and	consequently,	water.	The	formation	of	ice	crystals	within	the	solvent	filled	pores	of	a	protein	crystal	can	disrupt	the	crystal	lattice,	distorting	its	diffractive	properties.	Therefore,	 it	 is	necessary	 to	protect	 crystals	with	 cryoprotectants.	These	 include	glycerol,	polyethylene	glycols	or	high	salt		(Bergfors,	1999).		
1.6.2	Properties	of	protein	crystals	
Protein	 crystals	 are	 formed	 via	 weak	 intermolecular	 interactions	 between	 each	individual	globular	protein	molecule.	These	intermolecular	interactions	are	sparse	relative	to	the	size	of	the	protein	molecule,	leading	to	a	low	contact	to	volume	ratio.	This	results	in	protein	crystals	that	are	often	soft	and	fragile.	As	proteins	have	an	irregular	 surface,	 large	 solvent	 filled	 pores	 are	 present	 in	 between	 individual	molecules.	 The	 solvent	 molecules	 are	 mostly	 disordered	 and	 therefore	 do	 not	contribute	to	the	diffraction	pattern.		
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The	 fundamental	 property	 exploited	 in	 a	 diffraction	 experiment	 is	 the	 internal	symmetry	of	 the	 crystal.	The	 regular,	periodic	arrangement	of	protein	molecules	within	the	crystal	is	necessary	to	produce	the	discrete	X-ray	diffraction	that	permits	determination	of	a	structure.	There	are	 limited	conformations	 in	which	a	protein	molecule	 can	 be	 arranged	 into	 a	 crystal	 lattice.	 The	 translation	 periodicity	 and	internal	 symmetry	 requirements	 allow	 for	65	possible	 arrangements	 for	 a	 chiral	protein	molecule	in	3-dimensional	space.	The	internal	symmetry	of	a	crystal	is	an	important	 feature	 to	 consider	when	 collecting	 diffraction	 data	 from	 a	 crystal,	 as	more	 degrees	 of	 data	 will	 need	 to	 be	 acquired	 from	 crystals	 with	 lower	 order	symmetry	(Chernov,	2003).					
1.6.3	Basics	of	X-ray	diffraction	
Unlike	 individual	 atoms,	 irradiation	 of	 a	 crystal	 from	 specific	 angles	 will	 yield	positive	 diffraction	 data	 often	 referred	 to	 as	 reflections.	 This	 property	 of	 crystal	diffraction	 is	 expressed	 by	 the	 Bragg	 equation	2 dsin 𝜃 = 𝑛𝜆 	(Bragg	 and	 Bragg,	1913).	 Bragg’s	 law	 outlines	 the	 conditions	 when	 constructive	 and	 destructive	scattering	occurs.	Coherent	constructive	interference	only	occurs	when	a	beam	of	X-rays	(of	identical	wavelength	and	phase)	falling	on	adjacent	lattice	planes,	that	the	extra	length	travelled	between	the	adjacent	lattice	planes	needs	to	be	an	integer	of	the	 wavelength	 of	 the	 irradiating	 x-ray.	 The	 position	 and	 distance	 between	 the	diffraction	 reflections	 are	 directly	 related	 to	 the	 crystal	 symmetry	 and	 unit	 cell	dimensions	(the	smallest	unit	of	the	crystal	whereby	the	crystal	could	be	rebuilt	by	simple	 translation).	 The	 information	 that	 allows	 resolution	 of	 the	 the	 atomic	structure	 is	 the	 intensity	 of	 the	 reflections.	 This	 value	 is	 directly	 related	 to	 the	underlying	 molecular	 transform	 in	 reciprocal	 space	 of	 the	 molecular	 electron	
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density	and	is	linked	to	the	real	space	electron	density	via	a	Fourier	transformation.		Due	to	the	experimental	parameters	the	phase	information	is	lost,	as	only	intensity	data	is	collected.	Therefore,	to	solve	the	structure	this	phase	information	must	be	obtained	 via	 supplementary	 experimentation.	 This	 includes	 multiple/single	isomorphous	 replacement,	 multiple/single	 wavelength	 anomalous	 dispersion	 or	molecular	replacement	(Taylor,	2003).		
1.6.4	Basics	of	structural	determination		
Electron	density	obtained	from	Fourier	transformation	of	the	reciprocal	space	data	is	presented	as	a	contoured	electron	density	map.	A	model	is	built	into	the	electron	density	map	using	standard	amino	acid	bond	lengths	and	geometries.		This	model	is	then	 refined	 against	 the	 electron	 density	map.	 During	 each	 cycle	 of	 refinement,	adjustments	are	made	to	the	phases	that	reduce	the	difference	in	the	calculated	and	observed	diffraction	patterns.	Adjustments	are	also	made	to	the	coordinates	of	the	model	 using	 maximum	 likelihood	 or	 dynamics	 simulations.	 Repeated	 cycles	 of	refinement	and	model	building	are	employed	in	order	to	obtain	the	final	structure.	To	ensure	the	refinement	process	does	not	bias	the	map	5-10%	of	the	collected	data	is	set	aside	and	not	refined	against.	This	is	then	used	to	monitor	any	biasing	of	the	map.			
1.6.5	Crystallisation	of	protein	ligand-complexes	
There	are	two	major	methods	for	crystallising	protein-ligand	complexes.	These	are	co-crystallisation	and	soaking.	The	soaking	method	exploits	the	solvent	filled	pores	that	are	characteristic	of	protein	crystals.	The	crystal	pores	allow	small	molecules	to	diffuse	 through	 the	crystal	and	bind	 to	 the	protein	 in	 situ.	However,	 there	are	
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some	limitations	to	this	method.	Large	molecules	may	not	be	able	to	diffuse	through	the	crystallographic	pores	and	conformational	changes	induced	by	ligand	binding	may	be	inhibited	by	crystallographic	packing	restraints	or	may	disrupt	the	crystal	making	it	unviable.	The	co-crystallisation	method	incorporates	the	ligand	of	interest	into	the	protein	crystallisation	mix.	If	successful,	the	protein	will	crystallise	with	the	ligand	bound.	 Proteins	 are	 often	 crystallised	with	 ligands	when	 crystallisation	 is	aided	 by	 the	 stabilisation	 of	 the	 protein	 in	 a	 single	 conformation	 due	 to	 ligand	binding.	However,	some	ligands	may	also	precipitate	out	in	the	crystallisation	mix	or	crystallise	independently	of	the	protein	(Hassell	et	al,.	2007).						
1.7	Introduction	to	Small	angle	X-Ray	Scattering		
Small	angle	X-ray	scattering	(SAXS)	is	a	biophysical	technique	that	can	be	employed	to	study	the	size,	shape,	and	dynamics	of	molecules	in	solution.	The	wavelength	of	X-rays	 are	 smaller	 than	 that	 of	 the	 protein	 molecules	 studied.	 Therefore,	 X-ray	scattering	can	give	rise	to	inference	effects	that	lead	to	an	angular	dependence	of	X-rays	 scattering,	 revealing	 structural	 information	 about	 the	 sample.	 SAXS	experiments	are	frequently	performed	at	synchrotrons	on	purpose-built	beamlines.	Typically,	 a	 sample	 concentration	 of	 between	 0.5	 and	 10mg/ml	 is	 used.	 In	 this	dissertation	 Size	 exclusion	 chromatography	 -	 Small	 angle	 X-ray	 scattering	 (SEC-SAXS	)	is	utilised.	This	method	employs	High	Performance	Liquid	Chromatography	(HPLC)	where	the	sample	flows	through	a	size	exclusion	column	before	entering	the	X-ray	 beam.	 In	 contrast	 to	 X-ray	 crystallography,	 in	 SEC-SAXS	 the	 molecules	 in	solution	 are	 arranged	 randomly	 in	 different	 orientations.	 The	 data	 collected	 is	therefore	 spherically	 averaged,	 creating	 a	 low-resolution	model	 of	 the	molecule	studied.	 Scattering	 data	 is	 collected	 on	 a	 detector	 and	 a	 radial	 integration	 is	
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performed	to	produce	a	one-dimensional	SAXS	profile.	The	scattering	profile	is	the	scattering	intensity	plotted	against	a	function	of	the	angular	dependants	known	as	q	(q=4πsinθ/λ).	This	value	can	be	converted	to	real	space	with	an	indirect	Fourier	transformation.	 Significant	 scattering	 from	 the	 solvent	 is	 observed	 in	 a	 SAXS	experiment	 and	must	 be	 subtracted	 from	 the	 scattering	 profile	 in	 order	 to	 gain	accurate	insight	into	the	molecule	of	interest.	The	intensity	of	the	data	collected	is	dependent	on	the	interparticle	interactions	within	the	solution.	To	obtain	data	on	the	size	and	shape	of	a	single	particle,	there	must	be	no	interparticle	interactions	and	a	mono-disperse/non-aggregated	sample	is	required	(Svergun	and	Koch,	2003).	Expected	 scattering	 profiles	 can	 be	 calculated	 computationally	 for	 any	 given	molecular	 shape.	 This	 process	 is	 widely	 used	 to	 compare	 SAXS	 data	 to	 models	obtained	in	NMR,	crystallography	and	other	techniques.	This	same	process	can	go	in	the	other	direction	to	obtain	a	low-resolution	(bead	model)	structure	from	the	SAXS	data	collected	(Franke	and	Svergun,	2009).				
	
1.7.1	Analysis	of	SAXS	graphs														There	are	established	plots	that	are	used	in	the	analysis	of	SAXS	data	and	the	three	most	essential	of	these	are	the	Guinier	plot,	Kratky	plot	and	Distance	distribution	function	(REF).	The	Guinier	plot	is	used	to	determine	the	Radius	of	gyration	(Rg)	of	the	molecule	being	studied.	The	Rg	is	an	estimation	of	the	size	of	the	molecule	being	studied.	It	is	the	root	mean	square	distance	of	all	the	distances	to	the	centre	of	mass	of	the	scattering	molecule.	The	angular	dependence	of	scattering	intensity	close	to	that	of	the	incident	beam	should	give	a	linear	slope	equal	to	Rg2/3.	This	is	known	as	the	Guinier	region	and	is	obtained	from	the	Guinier	plot	(REF).	The	Kratky	plot	is	employed	to	examine	the	flexibility	of	a	protein	but	also	gives	some	information	on	
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the	type	of	protein	being	studied,	for	example	if	the	protein	is	multidomain	or	single	globular	(Figure	8A)	(REF).	The	Distance	distribution	function	often	referred	to	as	the	P(r)	plot	is	the	indirect	fourier	transform	from	the	scattering	function	(I	vs	Q),	and	 therefore	 represents	 the	 real	 space	 representation.	 Where	 the	 distance	distribution	function	meets	the	x-axis	(rÅ)	this	is	equal	to	the	maximum	dimensions	(D-max)	of	the	scattering	molecule.	The	shape	of	the	distance	distribution	function	also	reveals	aspects	of	the	shape	of	the	molecule	being	studied	(figure	8B)	(REF).	
	
Figure	4.	A)	The	different	shaped	curves	produced	by	different	types	of	protein	on	a	Kratky	
plot.	 B)	 The	 distance	 distribution	 function	 that	 would	 be	 expected	 from	 different	 shape	
proteins.	Ref	for	figure	
 
1.8	Introduction	to	Assays	and	Inhibitors	
1.8.1	Malachite	green	Assay	
Inositol	Monophosphatase	produces	free	phosphate	from	IP1.	The	enzymatic	assay	used	in	this	thesis	measures	the	concentration	of	 free	phosphate	using	malachite	green	reagent	(BIOMOL®GREEN).	Free	phosphate	forms	a	complex	with	malachite	green	and	absorbs	 light	at	wavelength	of	λ=	620-640	nm.	The	absorbance	at	 this	wavelength	 is	 directly	 related	 to	 the	 phosphate	 concentration.	 Therefore,	 the	absorbance	can	then	be	measured	and	IMPase	activity	quantified	with	respect	 to	phosphate	production.	This	assay	is	an	endpoint	assay,	therefore,	IMPase	activity	is	
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stopped	prior	to	the	measurement	(Itaya	and	Ui,	1966;	D'Angelo,	Crutchfield,	and	Vandiviere,	2001;	O'Toole	et	al.,	2007).			
1.8.2	Thermal	shift	Assay	
Thermal	shift	 is	a	biophysical	assay	that	monitors	the	melting	temperature	(Tm),	the	 temperature	at	which	 the	protein	 loses	 it	globular	 fold,	of	 the	 target	protein.	Most	proteins	have	a	hydrophobic	core,	and	this	is	the	major	driving	force	of	protein	folding.	The	hydrophobic	core	 is	not	solvent	exposed.	 In	 this	assay	 the	sample	 is	slowly	 heated	 causing	 the	 protein	 to	 unfold	 (denature)	 and	 the	 hydrophobic	residues	become	exposed.	The	denaturation	of	the	protein	can	be	monitored	with	the	use	of	a	 fluorescent	dye	that	binds	to	the	exposed	hydrophobic	residues.	The	melting	temperature	of	a	protein	can	fluctuate	if	it	is	bound	to	a	ligand.	The	binding	of	a	ligand	frequently	stabilizes	the	fold	of	a	protein,	thereby	increasing	the	melting	temperature	of	a	protein.	However,	some	ligands	can	stabilise	the	fold	but	have	the	opposite	effect	on	melting	temperature.	This	fluctuation	of	the	melting	temperature	of	the	target	protein	can	be	used	to	monitor	ligand	binding	(Pantoliano	et	al.,	2001).			
1.8.3	Saturation	Transfer	Difference	(STD)	Nuclear	Magnetic	Resonance	
(NMR)	
	Saturation	 Transfer	 Difference	 Nuclear	 Magnetic	 Resonance	 (STD-NMR)	 is a	popular	technique	in	drug	discovery	projects	and	can	be	used	for	both	screening	and	ligand	binding	conformation.	STD-NMR	is	a	technique	that	measures	the	signal	from	the	 ligand	 rather	 than	 from	 the	protein.	 In	 an	STD-NMR	experiment,	 the	protein	signal	is	selectively	saturated,	and	this	saturation	can	transfer	from	the	protein	to	a	binding	 ligand	 through	 the	 nuclear	Overhauser	 effect.	Hydrogen	 from	 the	 ligand	needs	to	be	≤5Å	to	the	protein	for	transference	to	take	place.		A	difference	spectrum	
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is	produced	by	subtracting	a	saturated	spectra	from	the	off-saturation	spectra.	If	a	ligand	binds	to	the	protein	there	will	be	a	difference	between	the	ligand	signals	in	the	saturated	spectra	compares	to	the	off-saturation	spectra,	producing	peaks	in	the	difference	spectra	(Mayer	and	Meyer,	2001;	Viegas	et	al.,	2011).	
1.8.4	Overview	of	inhibitors		
Inhibitors	are	molecules	that	bind	to	and	decrease	the	activity	of	a	target	protein	such	as	an	enzyme	or	ion	channel.	There	are	a	variety	of	different	types	of	inhibitors	that	have	different	biochemical	properties	and	may	be	useful	for	different	types	of	protein	targets.	In	the	following	section	I	will	focus	on	enzyme	inhibition.			
1.8.4.1	Competitive	Inhibitors	
Competitive	 inhibitors	 in	 relation	 to	enzymes	 refer	 to	 inhibitors	 that	bind	 to	 the	active	site	of	the	enzymes.	As	the	inhibitor	and	substrate	bind	to	the	same	site,	they	are	in	competition	with	each	other	for	that	binding	site.	Competitive	inhibitors	often	have	similar	chemical	properties	to	the	substrate	they	are	competing	with.	This	is	a	reflection	of	the	fact	that	they	are	binding	to	the	same	site	on	the	protein	and	usually	make	 the	 same	or	 similar	 interaction.	The	majority	of	 competitive	 inhibitors	 are	reversible	with	non-covalent	interactions	made	between	the	protein	and	inhibitor.	As	 reversible	 competitive	 inhibitors	 are	 in	 competition	 with	 the	 substrate,	 the	higher	 the	 substrate	 concentration	 the	 higher	 the	 concentration	 of	 inhibitor	required	to	inhibit	the	enzyme.	Irreversible	competitive	inhibitors	stop	the	enzyme	binding	and	catalysing	any	additional	substrate	and	frequently	form	a	covalent	bond	with	the	target	protein.	Irreversible	competitive	inhibitors	have	different	properties	to	reversible	competitive	 inhibitors,	such	as	 taking	 longer	 to	reach	 full	 inhibition	
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and	 higher	 substrate	 concentration	 resulting	 in	 more	 time	 required	 to	 reach	maximal	inhibition	(REFS).		
1.8.4.2	Non-competitive	inhibitors		
In	 contrast	 to	 competitive	 inhibitors,	 non-competitive	 inhibitors	 bind	 to	 a	 site	outside	of	the	active	site	and	are	therefore	not	in	competition	with	any	substrate.	Non-competitive	 inhibitors	 function	 either	 through	 binding	 to	 physiological	regulatory	 (allosteric)	binding	sites,	binding	 to	 the	enzyme	substrate	complex	or	covalently	binding	and	inhibiting	the	dynamics	of	the	protein.	Similar	to	competitive	inhibitors,	non-competitive	inhibitors	may	also	be	reversible	or	irreversible	(REF).		
1.8.4.4	In	situ	degradation			
A	relatively	novel	method	of	inhibiting	proteins	is	by	exploitation	of	the	ubiquitin	proteasome	 pathway.	 Proteolysis-targeting	 chimeras	 (PROTACs)	 are	 synthetic	chemicals	that	link	the	target	protein	to	an	E3	ligase	causing	the	ubiquitination	of	the	 target	 protein.	 This	 ubiquitination	 identifies	 the	 protein	 as	 a	 target	 of	 the	proteasome;	a	large	protein	complex	that	hydrolyses	surplus	or	damaged	proteins.	PROTACs	 have	 an	E3	 ligase	 ligand	 at	 one	 end	 and	 a	 target	 protein	 ligand	 at	 the	opposite	 end,	 linked	 together	 by	 a	 flexible	 chemical	 linker	 to	 produce	 a	 single	molecule.	The	majority	of	proteins	do	not	have	an	active	site	or	a	channel.	These	include	 scaffold	 proteins,	 cytoskeletal	 proteins	 and	 transcription	 factors	 and	therefore	 do	 not	 possess	 an	 active	 site	 that	 can	 be	 blocked.	 In	 this	 situation,		traditional	inhibitors	can	be	ineffective	and	therefore	the	use	of	a	PROTAC	may	be	more	successful	(Toure	and	Crews,	2016;	Ottis	and	Crews,	2017).					
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1.9	Overview	of	the	Drug	Discovery	Process			
The	drug	discovery	process	is	a	resource	intensive	and	time	intensive	process	that	has	a	low	success	rate.	To	launch	a	new	drug	to	the	market	takes	typically	10-18	years,	with	the	associated	costs	in	excess	of	a	billion	pounds	(DiMasi,	Hansen,	and	Grabowski,	2003).	The	experimental	 stages	of	 the	drug	discovery	process	can	be	split	into	three	overarching	categories:	
1. Molecule	discovery		2. Preclinical	development		3. Clinical	development		
Each	stage	is	made	up	of	multiple	steps.	Fundamentally	the	drug	discovery	process	is	a	periodic	stepwise	path	with	clear	aims.		
The	molecule	discovery	stage	typically	takes	between	2-5	years	and	is	made	up	of	four	steps.	The	first	and	second	steps	are	target	identification	and	validation.	Target	identification	consists	of	identification	of	a	drug	target	usually	by	the	discovery	of	a	protein	or	gene	involved	in	a	particular	disease.	The	target	is	then	validated	using	typical	approachs	such	as	studies	of	knockout	models	of	the	target	protein.	The	third	and	 fourth	 stages	 are	 lead	 identification	 and	 optimization.	 The	 initial	 chemical	matter	is	usually	found	by	screening	thousands	of	chemicals	for	inhibition	activity	or	protein	binding.	Once	the	initial	chemical	matter	is	identified	it	is	then	optimized	by	medicinal	chemistry	efforts,	in	order	to	increase	affinity	and	potency	(REF).		
After	 a	 potent	 compound	 has	 been	 developed	 it	 is	 then	 progressed	 into	 the	preclinical	development	phase.	This	phase	aims	to	meet	all	of	the	requirements	for	
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the	 compound	 to	be	 tested	 in	humans.	There	are	 four	main	 subcategories	of	 the	preclinical	 development	 phase.	 These	 are	 preliminary	 toxicological	 testing,	pharmacokinetic	 testing,	 pharmacological	 testing	 and	 feasibility	 studies	 for	 large	scale	production	of	the	compound.	This	stage	frequently	takes	between	1	to	3	years	and	involves	testing	the	compound	in	 in	vitro	assays	and	on	non-human	animals.	The	aim	is	to	attempt	to	minimise	any	safety	risks	in	human	clinical	trials	and	test	compound	 efficacy	 in	 disease	 models.	 Compounds	 at	 this	 stage	 may	 still	 be	optimized	 in	 an	 effort	 to	 improve	 the	 pharmacokinetic	 properties.	 However,	compounds	with	obvious	toxicity	or	pharmacological	hazards	are	dropped	at	this	stage	(REF).		
After	a	compound	has	successfully	been	shown	to	be	safe	in	non-human	animals,	it	progresses	into	the	clinical	development	phase.	This	is	composed	of	three		clinical	trial	phases	known	as	Phases	1,	2	and	3.	The	phases	are	performed	sequentially,	and	the	compound		must	pass	the	previous	phase	before	moving	onto	the	next.	A	phase	1	clinical	trial	examines	the	tolerability	and	potential	side	effects	of	the	compound,	as	well	as	the	in	vivo	pharmacokinetics.	The	fundamental	purpose	of	Phase	1	is	to	monitor	 the	 safety	 of	 the	 compound	 and	 calculate	 safe	 dosage	 regimes.	 Phase	 2	clinical	 trials	 are	 small	 scale	 patient	 trials	 to	 assess	 the	 initial	 efficacy	 of	 the	compound	and	determine	effective	dosage	regimes.	Phase	2	will	also	build	on	the	safety	evidence	obtained	in	phase	1	trials	by	evaluating	long	term	toxicology.	Phase	3	are	large-scale	controlled	clinical	trials.	At	this	stage	the	compound	will	also	be	a	compared	 to	alternative	drugs,	 if	 available.	The	clinical	development	 stage	 is	 the	most	expensive	stage	of	drug	development	and	usually	takes	between	5	to	7	years	to	 complete.	 In	 order	 for	 a	 compound	 to	 be	 approved	 it	 has	 to	 have	 advantages	
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above	 those	 other	 drugs	 already	 on	 the	 market,	 such	 as	 being	 cheaper	 to	manufacture	or	having	better	efficacy.	Alternatively	the	compound	may	address	an	unmet	clinical	need.	If	the	compound	is	approved	for	the	market,	there	is	a	process	of	 continual	 surveillance	 of	 patients.	 This	 is	 often	 referred	 to	 as	 phase	 4.	 The	purpose	of	 this	 is	 to	 to	monitor	 any	 side	 effects	or	 long-term	 toxicity	 issues	 and	identify	drug	interactions	that	have	not	or	could	not	be	identified	during	the	drug	development	process	(REF).		
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1.10	Aims	and	Project	structure		
The	aims	of	this	project	were	to	explore	the	calbindin-IMPase	interaction	and	to	use	this	information	to	aid	in	the	development	of	a	range	of	novel	chemical	matter	for	development	 into	 potential	 IMPase	 inhibitors.	 Four	 lines	 of	 investigation	 were	tackled	 in	 the	 following	 chapters;	 the	 first	 two	 examining	 the	 calbindin-IMPase	interaction	and	the	final	two	aiming	to	identify	novel	inhibitors	and	chemical	matter.	This	project	is	divided	into	two	sections.	The	first	section	consists	of	the	biological	allosteric	 modulation	 of	 IMPase,	 and	 second	 section	 covers	 pharmacological	allosteric	modulation	of	IMPase	(Figure	9).		
	
Figure	5.	The	structure	of	this	thesis	is	illustrated	in	a	tree	diagram.	The	project	is	divided	
into	two	sections:		Biological	and	Pharmacological.	
	
1.10.1	Biological	data	The	biological	 section	of	 this	 thesis	explores	 the	 structure	of	 the	 IMPase	binding	partner	calbindin-D28k.	Currently,	only	an	NMR	model	of	 the	rat	calbindin-D28k	has	been	solved	(ref).	Despite	published	attempts	 to	secure	a	crystal	structure,	a	structure	has	failed	to	be	produced,	as	a	phasing	solution	could	not	be	found	(ref).	After	 purifying	 human	 calbindin-D28k,	 SAXS	 data	 indicated	 that	 there	 were	differences	between	the	NMR	models	of	calbindin-D28k	compared	to	the	SAXS	data	
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(ref).	The	NMR	model	does	not	allow	direct	visualization	of	calcium	binding	sites.	This	is	an	important	structural	feature	as	a	central	function	of	calbindin-D28k	is	as	a	calcium	buffering	and	sensing	protein.	Therefore,	an	important	project	aim	was	to	produce	 a	 crystal	 structure	 of	 calbindin-D28k.	 To	 gain	 an	 understanding	 of	 the	calbindin-IMPase	interaction	it	would	be	important	to	have	the	most	accurate	model	of	both	binding	partners.		A	 second	 aim	of	 the	 biological	 data	 section	 of	 the	project	was	 to	 create	 a	 fusion	protein	using	a	flexible	amino	acid	linker.	The	use	of	fusion	proteins	to	study	protein	complexes	is	well	established	and	has	yielded	both	NMR	and	crystal	structures	(ref).	Fusion	of	the	proteins	should	stabilize	the	complex	and	this	 is	particularly	useful	when	protein	interactions	are	of	a	low	affinity.	The	fused	complex	is	postulated	to	have	 increased	 catalytic	 activity	 compared	 to	 IMPase	 alone.	 (ref	 or	 is	 this	 your	theory?).	These	studies	would	confirm	that	the	activating	effect	of	calbindin-D28k	on	IMPase	is	at	a	one	to	one	concentration	ratio	(ref??).			
1.10.2	Pharmacological	data	Despite	the	identification	of	IMPase	in	the	1970s	as	a	potential	target	of	lithium	(ref),	the	development	of	the	pharmacology	of	IMPase	has	remained	sluggish.	IMPase	has	proven	 intractable	 to	 traditional	 drug	 discovery	 approaches.	 The	 inhibitors	 that	have	been	identified	to	date	(lithium,	ebselen	and	L-690,330)	all	have	issues	with	polypharmacology	 or	 undesirable	 physiochemical	 properties.	 Both	 lithium	 and	ebselen	have	a	polypharmacological	profile;	 lithium	because	 it	 is	a	 small	 ion	and	ebselen	because	it	is	small	and	reactive.	L-690,330	is	very	polar	and	therefore	lacks	cell	and	CNS	penetration.	In	the	pharmacological	branch	of	the	project,	I	aim	firstly	to	 identify	 novel	 binding	 sites	 outside	 the	 active	 site	 that	 may	 be	 of	 potential	
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therapeutic	benefit.	This	will	be	attempted	by	the	use	of	a	crystallographic	fragment	soaking	screen.	Furthermore,	 I	aim	to	explore	potential	novel	binding	sites	using	site-directed	 mutagenesis.	 Lastly,	 due	 to	 the	 relatively	 recent	 discovery	 of	 the	inhibition	of	 IMPase	by	ebselen,	 I	 aim	 to	 screen	 reactive	 compound	 inhibitors	 in	order	to	identify	novel	chemical	matter	for	future	medicinal	chemistry	efforts.			
1.10.3	Chapter	Aims	
1.10.3.1	 Chapter	 2:	 The	 X-ray	 structure	 of	 human	 calbindin-D28K:	 an	
improved	model.		
To	 express,	 crystalise	 and	 structurally	 resolve	 the	 IMPase	 binding	 partner	Calbindin-D28k.	 This	 is	 the	 first	 structure	 produced	 of	 the	 human	 isoform	 and	allows	 direct	 visualization	 of	 the	 calcium	 binding	 sites	 of	 Calbindin-D28k.	Understanding	 the	 structure	 function	 relationship	 of	 Calbindin-D28k	 could	 give	insights	that	will	allow	further	understanding	of	the	Calbindin-IMPase	interaction.	
1.10.3.2	 Chapter	 3:	 Fusion	 Protein	 Exploration	 of	 the	 Calbindin-IMPase	
Interaction.		To	 develop	 fusion	proteins	 that	mimic	 the	 Calbindin-IMPase	 interaction	 and	use	these	 in	 structural	 analysis	 in	 order	 to	 evaluate	 a	 previously	 published	 in	 silico	docking	model,	and	gain	insights	into	the	biophysical	properties	of	the	Calbindin-IMPase	protein	complex.		
1.10.3.3	 Chapter	 4:	 Exploration	 of	 A	 Novel	 Fragment	 Binding	 Site	 at	 the	
Homodimer	Interface	of	IMPase.	
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To	use	crystallographic	screening	to	identify	novel	fragment	binding	sites	of	IMPase.	To	further	evaluate	the	identified	fragment	binding	sites	using	site-directed	mutagenesis	and	crystallography.	
	
	
	
1.10.3.4	Chapter	5:	Isothiazolinone	Inhibition	of	IMPase.	
		To	expand	the	range	of	isothiazolinone	inhibitors	identified	by	creating	a	screening	library	based	on	the	previously	identified	inhibitor	ebselen.	Any	hits	identified	by	the	screen	will	then	have	compound	properties	and	mechanism	of	action	explored	by	the	use	of	biochemical	and	biophysical	assays.																				 	
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The X-ray Structure of Human Calbindin-D28K: An Improved 
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Abstract:	Calbindin-D28K	is	a	widely	expressed	calcium	buffering	cytoplasmic	protein	and	is	involved	in	many	physiological	processes.	It	has	been	shown	to	interact	with	other	proteins,	 suggesting	a	role	as	a	calcium	sensor.	Many	of	 the	 targets	of	Calbindin-D28K	are	of	therapeutic	interest,	for	example,	IMPase,	the	putative	target	of	lithium	therapy	in	bipolar	disorder.		Presented	here	is	the	first	crystal	structure	of	human	Calbindin-D28K	 (6FIE).	 There	 are	 significant	 deviations	 in	 the	 tertiary	 structure	when	compared	to	the	NMR	structure	of	rat	Calbindin-D28K	(2G9B),	despite	98%	sequence	 identity.	 SAXS	 indicates	 the	 crystal	 structure	 better	 predicts	 the	properties	 of	 Calbindin-D23K	 in	 solution	 compared	 to	 the	 NMR	 structure.	 We	present	 here	 the	 first	 direct	 visualization	 of	 the	 calcium	 binding	 properties	 of	Calbindin-D28K.	Four	of	the	six	EF-hands	(EF)	that	make	up	the	proteins	secondary	structure	 contain	 a	 calcium-binding	 site.	 Two	 distinct	 conformations	 of	 the	 N-terminal	EF1	calcium-binding	site	were	identified	using	long-wavelength	calcium-SAD.	 This	 flexible	 region	 has	 previously	 been	 recognized	 as	 a	 protein-protein	
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interaction	 interface.	 SAXS	 data	 collected	 both	 in	 the	 presence	 and	 absence	 of	calcium	 indicates	 that	 there	 are	 no	 large	 structural	 differences	 in	 the	 globular	structure	of	Calbindin-D28K	between	the	calcium	loaded	and	un-loaded	protein.		
Introduction:	Calbindin-D28K	 is	 a	 major	 calcium	 buffering	 cytoplasmic	 protein	 expressed	 at	particularly	 high	 levels	 in	 the	 central	 nervous	 system	and	 absorptive	 epithelium	(gut	 and	 kidney)(Schmidt	 2012).	 Calcium	 signaling	 is	 tightly	 regulated	 and	 is	involved	 in	 a	 myriad	 of	 physiological	 processes	 and	 consequently	 calcium	deregulation	 is	 a	 key	 factor	 in	 the	 pathogenesis	 of	 many	 diseases,	 such	 as	Alzheimer’s	 disease	 (Bojarski,	 Herms,	 and	 Kuznicki	 2008;	 Kook	 et	 al.	 2014).	Calbindin-D28K	was	 first	 identified	 in	 the	 intestine,	 colon,	 kidney	 and	 uterus	 of	
gallus	gallus	domesticus	(chicken)	(Wasserman,	Corradino,	and	Taylor	1969),	where	it	 is	 involved	 in	 the	 transcellular	 movement	 of	 calcium	 across	 the	 absorptive	epithelium	such	as	those	found	distal	convoluted	tubules	of	the	kidney	(Lambers	et	al.	2006).	Calbindin-D28K	 is	also	highly	expressed	 in	 the	central	nervous	system	(CNS),	 where	 it	 contributes	 up	 to	 1.5%	 of	 total	 soluble	 protein	 (Christakos,	Gabrielides,	and	Rhoten	1989;	Berggard,	Szczepankiewicz,	et	al.	2002).	In	chicken	kidney	cells	the	expression	of	Calbindin-D28K	is	vitamin-D	dependent	and	this	 is	true	for	other	absorptive	cells	(Clemens	et	al.	1989),	this	is	not	the	case	however	in	the	CNS	(Arnold	and	Heintz	1997).	Calbindin-D28K	has	been	reported	to	regulate	the	depolarization-stimulated	release	of	insulin	from	pancreatic	b-cells	through	the	regulation	of	 the	 cytoplasmic	 calcium	concentration	 (Sooy	 et	 al.	 1999).	 It	 is	well	documented	in	the	literature	that	Calbindin-D28K	has	neuroprotective	properties	in	the	CNS	(Yenari	et	al.	2001;	Yuan	et	al.	2013;	Sun	et	al.	2011),	and	recently	it	has	
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been	 demonstrated	 that	 its	 depletion	 in	 an	 Alzheimer’s	 disease	 mouse	 model	accelerates	 neuronal	 loss,	 apoptosis	 and	 mitochondrial	 dysfunction	 (Kook	 et	 al.	2014).		It	 has	 been	 shown	 that	 Calbindin-D28K	 interacts	 with	 a	 variety	 of	 proteins	 of	therapeutic	 interest	 (Schmidt	 2012).	 Calbindin-D28K	 binds	 and	 increases	 the	catalytic	activity	of	IMPase,	the	putative	target	of	lithium	therapy	in	bipolar	disorder	(Berggard,	Szczepankiewicz,	et	al.	2002).	IMPase	has	a	key	role	in	the	homeostasis	of	the	IP3	signaling	cascade	by	replenishing	free	myo-inositol	and	inhibition	of	this	enzyme	by	lithium	has	given	rise	to	the	Inositol	depletion	hypothesis	of	 lithium’s	efficacy	in	the	treatment	of	bipolar	disorder	(Harwood	2005).		More	recently	IMPase	inhibition	 has	 been	 shown	 to	 increase	 autophagy	 and	 the	 clearance	 of	 peptides	involved	in	the	pathogenesis	of	both	Huntington’s	and	Parkinson’s	diseases	(Sarkar	et	al.	2005),	indicating	that	the	inhibition	of	the	Calbindin-IMPase	interaction	maybe	of	therapeutic	benefit	in	these	diseases.	The	Calbindin-IMPase	interaction	has	been	modeled	 in-silico	 and	 the	 information	 used	 to	 develop	 a	 series	 of	 novel	 peptide	inhibitors	(Levi	et	al.	2013).	Calbindin-D28K	also	exhibits	anti-apoptotic	activity	by	binding	 to	 and	 inhibiting	 caspase-3	 (Bobay	 et	 al.	 2012;	 Bellido	 et	 al.	 2000).	Understanding	the	structural	basis	of	these	interactions	would	offer	possible	new	therapeutic	approaches	to	tackling	these	diseases.								Calbindin-D28K	belongs	to	a	superfamily	of	calcium	binding	proteins	that	includes	calmodulin	and	troponin	C.		All	of	these	proteins	have	a	high	a-helical	content	and	share	EF-hand	structures	that	constitute	the	calcium	binding	domains.	Calbindin-D28K	has	a	primary	structure	of	261	amino	acids	(Mr	~30kDa)	and	is	encoded	by	the	CALB1	gene.	In	2006	a	NMR	structure	of	the	Rattus	norvegicus	Calbindin-D28K	
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calcium-loaded	protein	revealed	for	the	 first	 time	the	tertiary	 fold	of	 the	protein,	Calbindin-D28K	is	mainly	𝛼-helical	and	these	make	up	six	EF-hand	motifs	that	are	held	together	in	a	single	globular	fold	via	hydrophobic	interactions	(Kojetin	et	al.	2006).	EF-hand	motifs	have	a	helix-loop-helix	topology	and	are	a	common	structural	characteristic	in	calcium	binding	proteins.	As	in	most	calcium-binding	proteins,	the	calcium	ion	is	coordinated	in	the	loop	region	between	the	two	helices	of	the	EF-hand,	for	Calbindin-D28K	a	calcium	ion	is	coordinated	in	four	out	of	the	six	EF-hand	motifs.	EF	hands	1,	3,	4	and	5	bind	calcium	with	high	affinity	(Akerfeldt	et	al.	1996;	Venters	et	al.	2003).	It	has	been	shown	that	Calbindin-D28K	undergoes	structural	changes	upon	calcium	binding,	indicative	of	a	calcium	sensing	protein	(Berggard,	Miron,	et	al.	 2002).	 However,	 both	 the	 APO	 and	 the	 calcium-loaded	 protein	 have	 exposed	hydrophobic	residues	on	the	surface	indicating	that	Calbindin-D28K	interacts	with	other	 proteins	 in	 both	 states	 (Berggård	 et	 al.	 2000).	 The	 high-resolution	 crystal	structure	 of	 human	 Calbindin-D28K	 reported	 here	 confirms	 these	 secondary	structural	findings	but	also	reveals	some	significant	differences	when	compared	to	the	 NMR	 structure	 of	 rat	 Calbindin-D28K.	 The	 human	 Calbindin-D28K	 structure	presented	here	allows	for	the	first	direct	visualization	of	calcium	ions	bound	by	the	protein.						
Method	
Cloning	and	expression	The	E.coli	 codon-optimized	Human	CALB1	gene	was	synthesized	and	cloned	 into	pET-15b	using	Nco1	and	BamH1	restriction	sites	 (Genscript).	A	polyhistidine	 tag	followed	by	a	human	rhinovirus	(HRV)	3C	protease	cleavage	sequence	was	included	
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in	 the	 synthetic	 construct	 directly	 5’	 of	 the	 Calbindin-D28K	 start	 codon.	 The	recombinant	 plasmid	 was	 then	 transformed	 into	 E.coli	 Rosetta	 2	 DE3	 cells	(Novagen)	 and	 plated	 on	 LB	 agar	 containing	 50μg/ml	 ampicillin.	 A	 100	 ml	preculture	was	 grown	 in	 LB	 broth	 (50ug/ml	 ampicillin)	 overnight	 at	 310K	with	shaking	 at	 200rpm.	 10ml	 of	 the	 preculture	 was	 used	 to	 inoculate	 the	 main	 1L	cultures	which	were	grown	at	310K	with	200rpm	shaking	to	an	OD600	~	0.6.	The	cultures	 were	 incubated	 on	 ice	 for	 2	 hours	 before	 Isopropyl	 β-D-1-thiogalactopyranoside		(IPTG)	induction	(0.4mM)	and	incubation	overnight	at	298K	with	shaking	at	180	rpm.		
Purification	Cells	were	harvested	and	spun	at	~	9500g	for	20mins	and	the	pellet	resuspended	in	sonication	 buffer	 (150mM	 NaCl,	 1mM	 MgCl,	 20mM	 Tris	 pH	 8.0	 and	 protease	inhibitor	 cocktail	 (cOmplete™,	 EDTA-free,	 Roche)).	 Cell	 lysis	 was	 achieved	 by	sonication	for	5	mins	with	5s	intervals	and	DNA	removed	by	the	addition	of	non-specific	 endonuclease	 (Benzonase®	 Nuclease,	 sigma)	 and	 incubation	 on	 ice	 for	10mins.	 The	 lysate	 was	 clarified	 at	 ~30,000g	 for	 20mins	 and	 the	 supernatant	retained.	 	 His-tagged	 recombinant	 protein	 was	 purified	 by	 cobalt	 affinity	chromatography	(Talon®	metal	affinity	resin),	the	clarified	lysate	supernatant	was	incubated	with	10ml	of	binding	buffer	equilibrated	resin	for	1hour	at	277K	(20mM	tris	pH	8.0,	150mM	NaCl	and	10mM	imidazole).	The	flow-though	was	removed	and	the	resin	was	washed	sequentially	with	7	column	volumes	of	binding	buffer.	The	bound	proteins	were	then	eluted	with	binding	buffer	containing	250mM	imidazole.	The	 his-tag	 was	 removed	 by	 incubation	 with	 rhinovirus	 (HRV)	 3C	 protease	overnight	 at	 277K.	 The	 cleaved	 protein	 was	 further	 purified	 by	 size	 exclusion	
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chromatography	on	a	Superdex	G75	in	5mM	tris	pH	8.0	1mM	CaCl2,	yielding	~	25-30mg	of	Calbindin-D28K	per	litre	of	culture.					
Crystallization	The	 Calbindin-D28K	 crystals	 that	 initially	 yielded	 the	 Ca-SAD	 phases	 where	replicated	from	previously	reported	crystallization	conditions	(crystal	condition	1:	~60mg	ml-1	protein,	1mM	CaCl,	5mM	Tris	pH	8.0	added	to	 in	a	ratio	of	1:1,	0.5M	ammonium	acetate,	0.1M	Bis-Tris	pH	6.5,	24%	PEG	3350)	(Zhang	et	al.	2008).	The	crystal	 structure	 reported	 here	 was	 obtained	 from	 the	 JCSG+	 crystallographic	screen	 from	 Molecular	 Dimensions	 (crystal	 condition	 2:	 0.1M	 Potassium	thiocyanate	 and	 30%	w/v	 PEG	 2000	MME)	 (Newman	 et	 al.	 2005).	 Recombinant	Calbindin-D28K	was	concentrated	 to	~40mg/ml	 in	1mM	CaCl2,	5mM	Tris	pH	8.0.	Crystallization	was	performed	in	MRC	2	well	crystallization	plates	(Swissci)	with	a	reservoir	 volume	 of	 50μl	 and	 a	 drop	 volume	 of	 0.2μl	 containing	 a	 1:1	 ratio	 of	precipitant	mix	to	protein.	The	crystallization	plates	were	incubated	at	293K	and	Calbindin-D28K	crystals	grew	within	a	week.									
Data	Collection	and	Processing	X-ray	 diffraction	 data	 was	 collected	 from	 Calbindin-D28K	 crystals	 grown	 under	condition	1	at	the	long-wavelength	macromolecular	crystallography	beamline	I23	at	the	Diamond	Light	Source	(Wagner	et	al.	2016).	The	Ca-SAD	phasing	experiment	was	performed	at	a	wavelength	of	3.02Å,	 close	 to	 the	Ca	K	absorption	edge	 (l	=	3.07	Å)	at	a	temperature	of	~50K.	In	total	8000	images	from	two	400°	sweeps	were	collected	 with	 0.1s	 exposure	 time	 using	 the	 inverse	 beam	 method.	 Data	 was	processed	with	the	DIALS/AIMLESS	packages	(Evans	and	Murshudov	2013;	Winter	et	al.	2018).	The	anomalous	substructure	of	five	calcium	atoms	could	be	determined	
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with	SHELXD	(Sheldrick	2008).	While	three	of	the	calcium	atoms	had	close	to	full	occupancy,	the	remaining	two	calcium	atoms	had	estimated	occupancies	of	around	50%	each.	After	density	modification,	over	90%	of	the	structure	could	be	built	into	the	resulting	experimental	electron	density	map.	However,	although	the	structure	was	 solvable	 it	 could	 not	 be	 refined	 owing	 to	 ambiguous	 N-terminal	 electron	density.	Therefore,	X-ray	diffraction	data	was	also	collected	from	a	Calbindin-D28K	crystal	grown	under	condition	2	at	the	Diamond	Light	Source	I03	beamline.	Data	was	 collected	 at	 100K	 with	 30%	 glycerol	 as	 cryoprotectant.	 1040	 images	 were	collected	with	an	omega	oscillation	of	0.10°	and	an	exposure	time	of	0.1s	per	image	at	a	wavelength	of	0.976A.	Diffraction	 intensity	data	was	 indexed,	 integrated	and	scaled	 using	 the	 autoPROC	 toolbox	 (Table	 1)	 (Vonrhein	 et	 al.	 2011).	 Molecular	replacement	 with	 the	 Ca-SAD	 model	 yielded	 a	 phasing	 solution	 using	 PHASER	(McCoy	 et	 al.	 2007).	 After	 cycles	 of	 model	 building	 and	 refinement	 using	BUCCANEER	and	the	CCP4	suite	of	programs	(Cowtan	2012;	Murshudov	et	al.	2011;	Emsley	et	al.	2010),	the	final	model	building	was	completed	in	COOT	and	refined	with	BUSTER	version	2.10.2.	
SEC-SAXS	SEC-SAXS	was	performed	at	 the	Diamond	Light	Source	B21	beamline.	Calbindin-D28K	samples	were	dialyzed	for	12h	at	277K	against	1L	of	sample	dialysis	buffer	(20mM	Tris	pH7.8,	150mM	NaCl,	±3mM	CaCl2)	prior	to	experiment.	A	45μl	sample	of	 11.5mg/ml	 Calcium	 loaded	 Calbindin-D28K	 or	 12.2mg/ml	 of	 un-loaded	Calbindin-D28k	was	 injected	 onto	 a	 Shodex	 KW-402	 size	 exclusion	 column	 pre-equilibrated	in	dialysis	buffer	and	run	at	a	flow	rate	of	0.16	ml/min.	Intensity	(I(q))	data	 was	 collected	 as	 the	 eluate	 passed	 through	 the	 X-ray	 beam	 and	 plotted	against	q	=	4psinq/l.	The	system	operated	with	an	exposure	time	of	3s	at	12.4	
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keV	 (1Å)	 using	 a	 Pilatus	 2M	 detector	 located	 at	 a	 distance	 of	 4m.	 Data	 was	analysed	 using	 the	 ATSAS	 and	 Scatter	 suite	 (Franke	 et	 al.	 2017;	 Franke	 and	Svergun	 2009;	 Kozin	 and	 Svergun	 2001).	 The	 FoXS	 web	 server	 was	 used	 to	compute	 the	 theoretical	 scattering	 profile	 from	NMR	 and	 crystal	 structures	 of	Calbindin-D28K	 for	 comparison	 with	 the	 experimental	 data	 (Schneidman-Duhovny	et	al.	2013,	2016).	No	changes	were	made	to	the	Calbindin-D28K	protein	models	used.	However,	 the	solvent	molecules	were	removed	from	the	structures.	They	were	used	as	deposited.	6FIE	has	extra	three	residues	at	the	N-terminal	due	to	the	cleavage	of	the	his-tag	at	the	3C	protease	cleavage	sequence.	The	SAXS	data	and	analysis	is	deposited	in	the	Small	Angle	Scattering	Biological	Data	Bank	(Valentini	et	al.	2015)	(accession	codes:	SASDDL6	for	calcium	loaded	Calbindin-D28K	and	SASDDM6	for	un-loaded).	
	
Results	
Calbindin-D28K	Crystal	structure	Refinement	 statistics	 for	 the	 Calbindin-D28K	 crystal	 structure	 (PDB	 code:	 6FIE)	(crystal	condition	2)	determined	to	a	resolution	of	1.51Å	are	presented	in	table	1.		
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Table	 1	 Crystallographic	 statistics	 and	merging	 statistics	 produced	 by	 autoPROC	 for	 PDB	
entry	 6fie	 (crystal	 condition	 2)	 and	AIMLESS	 for	 the	 calcium	 SAD	data	 set	 (crystallization	
condition	1).	Values	in	parentheses	are	for	the	highest	shell.	
	The	 disorder	 in	 the	 first	 Ca2+	 binding	 site	 is	 reflected	 in	 the	weaker	 side-chain	electron	density	in	the	N-terminal	EF-hands	accounting	for	the	relatively	high	RMSZ	score	for	this	structure	compared	to	other	x-ray	structures	determined	at	similar	resolution.	The	Ca-SAD	structure	determined	from	crystal	condition	1	allowed	the	direct	visualization	of	the	calcium	atoms	(Supplementary	Figure	1).	This	revealed	
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for	the	first	time	that	there	are	two	conformations	with	the	calcium	ions	are	located	4.7Å 	apart	 in	 the	 N-terminal	 EF-hand	 1	 (Figure	 10).	 Only	 one	 of	 these	 calcium-binding	 conformations	 was	 visible	 in	 the	 electron	 density	 for	 both	 crystal	conditions.	Due	to	the	increased	noise	in	this	region	the	calcium	coordinating	waters	were	 not	modeled	 around	 the	 disordered	 EF-hand	 1.	 	 Zhang	 et	 al	 (Condition	 1)	determined	a	space	group	to	be	C2	for	this	condition.	However,	this	repeated	crystal	had	a	space	group	of	P21212.	
Calcium	Binding	
At	1mM	Ca2+	concentration	Calbindin-D28K	binds	4	calcium	ions	at	each	of	the	EF1,	
EF3,	 EF4	 and	 EF5	 motifs	 with	 pentagonal	 bipyramidal	 coordination	 geometry	(Figure	 11).	 The	 coordinating	 residues	 starting	 from	 the	 N-terminal	 binding	residues	 of	 the	 calcium	 binding	 loops	 are	 aligned	 in	 Table	 2.	 Five	 amino	 acid	
Figure	10	The	two	Ca	atoms	in	EF1	from	the	substructure	
coordinates.	The	distance	between	the	peaks	is	shown.	There	
was	an	estimated	occupancy	of	50%	for	each	calcium.	The	Ca	
atom	in	pink	is	that	refined	in	PDB	entry	6fie.	
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residues,	a	backbone	interaction	and	a	water	molecule	complete	the	coordination	of	calcium	 in	 the	 EF1,	 EF4	 and	 EF5	 motifs.	 In	 contrast,	 the	 EF3	 motif	 utilizes	 an	interaction	 at	 Glu119	 (position	 9)	 instead	 of	 a	 water	 molecule	 to	 complete	 the	coordination	 of	 calcium.	 At	 position	 12	 all	 four	 calcium	 binding	 loops	 possess	 a	conserved	Glu	side-chain	that	acts	as	a	bidentate	coordinating	residue.	There	are	also	 non-calcium-binding	 conserved	 residues	 within	 the	 EF	 loops;	 there	 is	 a	conserved	glycine	at	position	6	and	either	a	leucine	or	isoleucine	at	position	8.	There	were	 no	 detectable	 differences	 in	 the	 SAXS	 scattering	 curves	 for	 calcium	 loaded	Calbindin-D28K	 and	 the	 calcium	 un-loaded	 protein	 (Supplementary	 Figure	 2),	indicating	 that	 the	 protein	 retains	 the	 same	 “kidney	 bean”	 shape	 post	 calcium-binding.		
Table	 2	 The	 aligned	 calcium-binding	 loops	 from	 calbindin-D28K	 starting	 from	 the	 first	
calcium-binding	 residue.	 Calcium-binding	 residues	 are	 highlighted	 in	 bold.	 A	 backbone	
carbonyl	group	binds	the	calcium	at	position	7.	
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Figure	6	The	four	EF-hand	calcium-binding	loops	of	calbindin-D28K.	Calcium-binding	amino	
acids,	 water	 molecules	 and	 calcium	 ions	 are	 shown,	 while	 the	 rest	 of	 the	 structure	 is	
illustrated	by	a	cartoon	representation.	Each	calcium	ion	is	coordinated	with	a	pentagonal	
bipyramidal	coordination	geometry,	 the	bonds	for	which	are	represented	by	a	dotted	line.	
The	EF1	 calcium	 is	 coordinated	by	Asp24,	Asp26,	 Ser28,	Tyr30,	Glu35	 and	water,	 the	 EF3	
calcium	by	Asp111,	Asp113,	Ser115,	Phe117,	Glu119	and	Glu122,	the	EF4	calcium	by	Asp155,	
Asn157,	Asp159,	Lys161,	Glu166	and	water,	and	the	EF5	calcium	by	Asp199,	Asp201,	Asn203,	
Tyr205,	Glu210	and	water.	
	
Structural	comparison						Calculated	scattering	curves	 for	6FIE	and	all	 ten	models	of	2G9B	were	compared	with	 the	 X-ray	 scattering	 curve	 of	 Calbindin-D28K	 in	 solution.	 Interestingly,	 the	crystal	 structure	curve	 fitted	 the	SAXS	curve	better	 than	 the	NMR	models	with	a	lower	Chi	value	of	1.19	versus	a	range	of	1.98-2.43	for	the	NMR	models	(figure	12A).		
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FatCat	pairwise	alignment	calculated	an	RMSD	of	3.2Å	between	the	crystal	structure	and	the	old	NMR	structure	(figure	12B)	(Ye	and	Godzik	2003).	The	distance	between	pairs	of	C𝛼	atoms	in	EF1	and	EF6	of	the	Calbindin	models	indicates	that	the	NMR	model	is	more	compact	when	compared	to	the	crystal	structure.	For	instance,	the	distance	between	Lys	34	Ca	and	Lys	224	Ca	is	35.59Å	and	27.79Å	for	6FIE	and	2G9B	(model	2)	respectively	(figure	12C).		
	
Figure	7	(a)	Log10	SAXS	intensity	versus	scattering	vector	q.	The	plotted	range	represents	the	
positive-only	data	within	the	specified	q-range	(red).	The	calculated	FoXS	scattering	curve	of	
PDB	entry	6fie	(blue)	and	calculated	FoXS	scattering	curves	for	the	first	five	models	of	PDB	
entry	2g9b	(green,	turquoise,	pink,	orange	and	black).	(b)	FATCAT	pairwise	alignment	and	
superimposition	(PDB	entry	6fie,	red;	PDB	entry	2g9b,	orange);	there	is	a	90		rotation	between	
the	two	images.	(c)	Measurement	of	the	distance	between	the	C		atoms	of	Lys34	and	Lys221;	
the	distance	is	shown	in	A	̊	
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Discussion	Calbindin-D28K	 is	 a	 widely	 expressed	 calcium	 binding	 protein	 possessing	 a	multiplicity	 of	 physiological	 functions.	 The	 expression	 is	 particularly	 high	 in	 the	central	 nervous	 system,	 and	 absorptive	 epithelial	 tissues	 where	 it	 buffers	 and	facilitates	 the	 movement	 of	 calcium	 (Clemens	 et	 al.	 1989;	 Schmidt	 2012;	Wasserman,	 Corradino,	 and	 Taylor	 1969).	 Recent	work	 has	 hinted	 at	 a	 possible	protective	role	of	Calbindin-D28K	in	inhibiting	apoptosis	and	necrosis	and	slowing	the	pathogenesis	of	neurodegenerative	diseases	such	as	Alzheimer’s	disease	(Yuan	et	al.	2013;	Yenari	et	al.	2001;	Sun	et	al.	2011;	Kook	et	al.	2014;	Bellido	et	al.	2000).	Not	only	does	Calbindin-D28K	act	as	a	buffer	for	calcium	ions	but	it	has	also	been	shown	 to	 interact	 with	 multiple	 protein	 targets	 to	 modulate	 their	 function	 or	catalytic	activity	(Shamir	et	al.	2005;	Berggard,	Szczepankiewicz,	et	al.	2002;	Lutz	et	al.	2003).	Here	we	report	the	first	X-ray	structure	of	Calbindin-D28K	allowing	for	the	first	time	a	detailed	high-resolution	analysis	of	its	calcium	binding	properties.	The	 human	 Calbindin-D28K	 X-ray	 structure	 also	 displays	 significant	 structural	differences	when	 compared	with	 the	 previously	 published	NMR	 structure	 of	 rat	Calbindin-D28K	molecule.	The	Human	and	Rat	isoforms	have	a	sequence	intensity	of	 98%.	 GLN44,	 ASP225,	 THR232	 and	 CYS257	 in	 human	 Calbindin-D28K	 are	changed	to	LEU44,	GLU225,	SER232	and	SER257	in	the	Rat	isoform.	These	residues	are	solvent	exposed	and	seem	not	to	explain	the	structural	difference	seen	between	the	two	structures.	Human	Calbindin-D28K	consists	of	six	EF-hand	motifs	arranged	in	 three	 pairs	 that	 maintain	 a	 globular	 structure	 stabilized	 by	 hydrophobic	interactions	 (Kojetin	et	al.	2006).	Four	EF-hands	bind	calcium	at	a	concentration	~1mM	 in	 the	 crystallization	 buffer,	 a	 concentration	 significantly	 higher	 than	 the	usually	nanomolar	physiological	 (cytosolic)	 concentration.	This	would	 imply	 that	
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the	 structure	presented	here	 represents	 a	 calcium-saturated	 form	of	 the	protein	with	respect	to	physiological	conditions	(Berridge	1997).	There	are	differences	in	the	calcium	binding	residues	between	the	individual	calcium	binding	loops,	despite	these	 differences	 in	 primary	 structure	 macroscopic	 studies	 have	 indicated	 that	Calbindin-D28K	 binds	 calcium	 in	 a	 non-sequential,	 parallel	 manner	 (Berggard,	Miron,	 et	 al.	 2002).	 However	 other	 spectroscopic	 studies	 have	 indicated	 the	opposite,	 that	 calcium	 binding	 is	 not	 simultaneous	 (Venters	 et	 al.	 2003),	 the	differences	 in	 the	 calcium	binding	mechanisms	observed	 in	 the	 crystal	 structure	support	this.	EF3	is	the	only	calcium-binding	loop	not	to	use	water	in	the	pentagonal	bipyramidal	coordination	of	the	calcium	ion;	glutamate	119	at	position	9	fulfills	this	role	instead.	Interestingly	both	EF1	and	EF4	also	have	glutamate	at	position	9	of	the	loop	but	these	are	not	involved	in	calcium	coordination.	Compared	to	the	existing	NMR	 model	 of	 Calbindin-D28K	 the	 X-ray	 structure	 is	 less	 compact	 with	 the	intramolecular	distances	increased	by	several	angstroms	across	the	molecule.	This	less	condensed	model	was	validated	by	SAXS	as	the	scattering	curve	of	the	protein	in	solution	was	better	predicted	by	the	crystal	structure.	This	is	surprising	as	it	is	often	assumed	that	crystal	structures	would	to	be	more	compact	than	solution	NMR	structures,	owing	to	crystal	packing	restraints.	The	high	overall	RMSD	score	of	3.2Å	also	reflects	significant	structural	differences	between	the	X-ray	structure	and	the	NMR	model.	 There	 are	 substantial	 differences	 in	 side	 chain	 conformations	 both	across	the	molecule	and	within	the	calcium	binding	loops.	Calcium	binding	at	the	N-terminal	 EF-hand	 (EF1)	 motif	 (where	 the	 electron	 density	 is	 more	 disordered)	appears	 to	be	more	 flexible	 that	 at	 the	other	 calcium	binding	 loops.	The	Ca-SAD	experiment	indicated	that	there	are	two	distinct	calcium	positions	in	the	N-terminal	EF-hand	with	 the	 calcium	 ions	 bound	 4.7Å	apart	 in	 Zhang’s	 (2008)	 crystal	 form	
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(crystal	condition	1).	Although	the	Ca-SAD	data	did	yield	a	phasing	solution,	the	dual	calcium–binding	geometry	precluded	full	structure	refinement.	Consequently,	new	crystal	growth	conditions	potentially	favoring	a	single	conformation	were	explored,	yielding	 crystal	 condition	 2	 in	 which	 residues	 are	 visible	 at	 the	 N-terminal.	Nevertheless,	 the	N-terminal	 flexibility	 still	manifests	as	 structural	disorder	with	higher	temperature	factors	values	in	this	region.	It	was	not	possible	to	build	the	two	conformations	into	the	electron	density	and	only	one	calcium-binding	site	is	visible	in	the	final	structure.	The	flexibility	of	this	region	could	be	important	in	facilitating	interactions	with	other	proteins.	Site-directed	mutagenesis	studies	have	previously	revealed	that	inositol	monophosphatase	(IMPase)	binds	to	the	aspartate	residues	24	&	26	in	this	 flexible	calcium-binding	 loop	(EF1)	of	Calbindin-D28K	(Levi	et	al.	2013).	Here	we	demonstrate	that	aspartate	24	&	26	are	involved	in	calcium	binding,	It	 has	 been	 demonstrated	 previously	 that	 the	 potentiation	 of	 IMPase	 catalytic	activity	 by	 Calbindin-D28K	 occurs	 irrespective	 calcium	 being	 present	 (Berggard,	Szczepankiewicz,	et	al.	2002).	The	peptide	binding	fragment	of	Ran-binding	protein	M	 has	 also	 been	 shown	 to	 induce	 large	 chemical	 shifts	 in	 the	 NMR	 spectrum	 of	Calbindin-D28K	 in	 the	 flexible	 N-terminal	 region	 (Lutz	 et	 al.	 2003).	 Docking	simulations	predict	binding	of	IMPase	at	that	the	grooved	structure	between	the	N	and	 C	 terminal	 EF-hand	 bundles	 of	 Calbindin-D28K	 where	 the	 X-ray	 structure	differs	the	most	from	the	NMR	model.			The	SAXS	scattering	curves	of	 calcium-loaded	and	un-loaded	Calbindin-D28K	are	essentially	 identical	 indicating	 similar	 globular	 structures	 for	 both	 states	 and	no	increase	in	flexibility.	Because	SAXS	is	a	low-resolution	technique	that	can	only	be	
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used	 to	 monitor	 large	 conformation	 changes,	 these	 findings	 do	 not	 preclude	significant	changes	at	the	intramolecular	scale.		
	
Conclusion		We	 present	 here	 the	 first	 X-ray	 structure	 of	 Calbindin-D28K	 at	 near-atomic	resolution.	Elucidation	of	the	calcium	coordination	geometry	in	the	EF-hand	loops	is	consistent	with	previous	reports	that	the	protein	has	four	calcium	binding	sites.	Ca-SAD	 at	 long	 wavelength	 demonstrated	 that	 the	 N-terminal	 EF-hands	 are	particularly	 flexible	 and	 possesses	 two	 calcium-binding	 conformations.	 Residues	that	have	previously	been	shown	to	be	involved	in	protein-protein	interactions	are	demonstrated	 to	also	coordinate	calcium,	potentially	bestowing	a	calcium	sensor	function	 on	 Calbindin-D28K.	 Calbindin-D28K	maintains	 the	 same	 globular	 shape	both	in	the	calcium-loaded	and	un-loaded	form.	There	is	also	no	significant	increase	in	the	flexibility	of	the	Calbindin-D28K	protein	in	the	un-loaded	form.	Intriguingly	6FIE	is	a	better	model	of	Calbindin-D28K	in	solution,	as	the	X-ray	scattering	curve	produced	 by	 the	 protein	 is	 better	 predicted	 by	 the	 crystal	 structure	 than	 the	previously	published	NMR	model	(2G9B).	We	surmise	that	the	high-resolution	X-ray	structure	of	Calbindin-D28K	presented	here	be	used	as	the	model	of	choice	for	future	experimentation	and	in	silico	modeling.						
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Exploration	of	the	Calbindin-IMPase	
Interaction	using	Fusion	Proteins	
		
James	W.	Noble	and	John	R.	Atack		
Abstract	Calbindin-D28k	 is	 a	 calcium	 buffering	 protein	 that	 is	 highly	 expressed	 in	 the	mammalian	CNS.	It	has	been	reported	that	calbindin-D28k	binds	to	and	increases	the	activity	of	IMPase	(ref).	IMPase	is	an	enzyme	that	is	involved	in	the	homeostasis	of	the	IP3	signalling	cascade	by	catalysing	the	final	dephosphorylation	of	inositol.	IMPase	has	been	implicated	in	the	therapeutic	mechanism	of	lithium	treatment	of	bipolar	disorder,	which	forms	the	basis	of	 the	 inositol	depletion	hypothesis	(ref).	Previously	reported	activity	assays	have	shown	that	calbindin-D28k	can	 increase	IMPase	activity	by	up	to	250	hundred-fold	in	conditions	that	are	unfavourable	for	IMPase	 activity	 (ref).	 In	 silico	 modelling	 and	 mutagenesis	 studies	 were	 later	performed	to	uncover	further	data	regarding	this	interaction	(ref).	Here	we	aim	to	explore	the	shape	and	properties	of	the	calbindin-IMPase	complex.	We	aim	to	confirm	that	calbindin-D28k	 increases	 IMPase	activity	at	a	one	 to	one	concentration	ratio.	We	have	created	several	fusion	proteins	of	calbindin-D28k	and	IMPase,	 connected	 by	 a	 flexible	 amino	 acid	 linker	 that	 fuses	 the	 termini	 of	 the	proteins	together.	A	variety	of	different	linker	lengths	and	orientations	were	tested.	The	 resulting	 fusion	 proteins	 have	 demonstrated	 relative	 activities	 of	 between	200%	to	400%	when	compared	to	IMPase	alone.	The	physical	properties	(flexibility,	shape	 and	 size)	 and	 low-resolution	 models	 of	 these	 fusion	 proteins	 were	 then	compared	to	the	previously	published	in	silico	models	using	SAXS.	Differences	in	the	shape	 of	 the	 complex	were	 observed	 between	 the	 low-resolution	 fusion	 protein	
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models	and	the	in	silico	model.	The	fusion	proteins	form	a	V-shaped,	longer	and	less	compact	 complex,	 in	 contrast	 to	 the	 linear	 in	 silico	 model.	 The	 fusion	 protein	presented	here	is	a	useful	tool	to	further	explore	this	protein-protein	interaction.			
	
Introduction	The	 calbindin-IMPase	 interaction	 was	 initially	 identified	 by	 affinity	chromatography,	using	immobilized	calbindin-D28k	and	phage-displayed	peptides	to	explore	the	calcium	sensing	function	of	calbindin-D28k	(Berggard	et	al.,	2002).	This	 interaction	 is	 of	 particular	 interest	 due	 to	 of	 the	 therapeutic	 significance	 of	IMPase	 in	the	treatment	of	bipolar	disorder.	 In	the	1970’s,	a	study	demonstrated	that	lithium	treatment	reduces	inositol	levels	in	the	brains	of	mammals	by	inhibition	of	 IMPase	 (ref).	 This	 formed	 the	 basis	 of	 the	 inositol	 depletion	 hypothesis	 of	lithium’s	 efficacy	 in	 the	 treatment	 of	 bipolar	 disorder	 (Berridge,	 Downes,	 and	Hanley,	1982;	Allison	et	al.,	1976;	Hallcher	and	Sherman,	1980).	More	recently	it	has	been	shown	that	inhibition	of	IMPase	leads	to	an	increase	in	autophagy	in	vitro	and	it	 has	 been	 proposed	 that	 this	 could	 be	 used	 therapeutically	 in	 the	 treatment	 of	neurodegenerative	disorders	in	which	protein	aggregation	plays	a	role	 in	disease	pathogenesis	 (Criollo	 et	 al.,	 2007;	 Sarkar	 et	 al.,	 2005).	 IMPase	 is	 a	 homodimeric	phosphodiesterase	enzyme	which	is	involved	in	the	phosphatidylinositol	signalling	cascade.	This	cascade	is	initiated	by	the	activation	of	GPCRs	causing	the	production	of	IP3	and	DAG	via	the	activation	of	PLC.	IP3	induces	the	release	of	calcium	from	intracellular	 stores	 and	 DAG	 activates	 PKC.	 IMPase	 performs	 the	 final	dephosphorylation	of	 inositol,	 recycling	 this	back	 to	 free	 inositol	 (Majerus	1992;	Streb	 et	 al.,	 1983;	 Furuichi	 et	 al.,	 1989;	 Newton,	 1995).	 IMPase	 is	 extremely	
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thermally	stable	displaying	a	Tm	of	79°C	and	each	monomer	possesses	an	αβαβα	topology	(Kraft	et	al.,	2018;	Bone,	Springer,	and	Atack,	1992).		Calbindin-D28k	 was	 initially	 identified	 as	 a	 calcium	 buffering	 protein	 in	 the	absorptive	epithelia	of	gallus	gallus	domesticus	(Wasserman,	Corradino,	and	Taylor	,	1969).	Calbindin-D28k	is	highly	expressed	in	the	human	central	nervous	system	(CNS),	 and	 binds	 to	 several	 other	 proteins	 indicating	 a	 role	 as	 a	 calcium	 sensor.	Binding	partner	proteins	include:	Ran-binding-protein-M,	caspase-3,	ATPases	and	cyclic	nucleotide	phosphodiesterases	(Bellido	et	al.,	2000;	Lutz	et	al.,	2003;	Morgan	
et	al.,	1986;	Reisner,	Christakos,	and	Vanaman,	1992).	Calbindin-D28k	is	composed	of	six	EF-hand	domains	that	exhibit	a	typical	helix-loop-helix	topology.	Four	out	of	the	 six	EF-	 hands	 that	 constitute	 calbindin-D28k	 coordinate	 a	 calcium	 ion	 in	 the	central	loop	(EF1,	EF3,	EF4	and	EF5).	The	six	domains	form	one	globular	structure	with	significant	flexibility	in	the	N-terminal	region	(Kojetin	et	al.,	2006;	Noble	et	al.,	2018).	The	calbindin-IMPase	interaction	has	been	shown	to	increase	the	activity	of	IMPase	by	up	to	250	fold	(ref).	Calbindin-D28k	increases	the	activity	of	IMPase	both	when	bound	 to	 calcium	 and	 in	 the	 apo	 form	 with	 a	 Kd	 of	 0.9	 μM	 (Berggard,	Szczepankiewicz,	 et	 al.,	 2002).	 The	 calbindin-IMPase	 interaction	 has	 been	demonstrated	 in	 situ	 in	 the	 spines	 and	 dendrites	 of	 cerebellar	 Purkinje	 neurons	(Schmidt,	Schwaller,	and	Eilers,	2005).	Mutagenesis	studies,	based	on	an	 in	 silico	model	of	 the	protein	complex,	demonstrated	 that	Asp24	and	Asp26	of	 calbindin-D28k	are	critical	for	the	activation	of	IMPase	in	biochemical	assays.		This	data	was	then	utilised	 to	design	peptide	 inhibitors	of	 the	 interaction	between	 IMPase	 and	calbindin-D28k	 (Levi	 et	 al.,	 2013).	 The	 interest	 in	 this	 interaction	 is	 of	 current	interest	because	of	the	therapeutic	potential	of	IMPase.	An	understanding	of	how	
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calbindin-D28k	 facilitates	 the	 increase	 in	 IMPase	 activity	 could	 reveal	 novel	methods	 for	 inhibiting	 IMPase.	This	 could	be	 either	by	 inhibition	of	 the	protein-protein	interaction	directly	or	by	discovering	more	about	the	structural	integrity	of	IMPase	that	could	then	be	exploited	pharmacologically.		Here	we	use	Gly-rich	flexible	amino	acid	linkers	to	connect	the	termini	of	calbindin-D28k	and	IMPase.	The	aim	is	to	produce	a	stable	protein	complex	that	can	be	used	for	further	structural	and	biochemical	analysis.	The	use	of	flexible	amino	acid	linkers	has	 been	 used	 previously	 to	 study	 the	 interactions	 of	 proteins.	 Linking	 proteins	together	 can	 help	 stabilise	 protein-protein	 interactions	 by	 increasing	 the	 local	concentration	 of	 the	 binding	 partner.	 This	 technique	 is	 often	 employed	 to	 study	proteins	 that	 have	 relatively	 weak	 affinities	 or	 transient	 interaction.	 Hence,	stabilising	 the	 complex	 allows	 the	 interaction	 to	 be	 studied	more	 easily	 (Reddy	Chichili,	 Kumar,	 and	 Sivaraman,	 2013).	 The	 creation	 of	 a	 fusion	 protein	 with	increased	catalytic	activity	will	confirm	existing	evidence	for	the	protein	interaction	between	calbindin-D28k	and	IMPase.	 	Here	we	also	employ	SAXS	to	gain	insights	into	the	shape	and	flexibility	of	the	protein	complex.		
	
Methods		
Fusion	Constructs	and	Protein	Expression		Two	sets	of	fusion	proteins	were	developed.		The	FP	group	where	calbindin-D28k	is	fused	to	the	C	terminal	of	IMPase	and	the	Cal-FP	group	where	IMPase	is	fused	to	the	C	 terminal	 calbindin-D28k	 (Figure	 13).	 The	 Gly-rich	 linkers	 were	 constituted	 of	repeats	of	an	11	amino	acid	polypeptide	 linker	 (GGGSASGGGSG).	This	 linker	was	designed	 based	 on	 previously	 reported	 studies	 (Reddy	 Chichili,	 Kumar,	 and	Sivaraman,	2013).	Protein	 expression	was	performed	 in	 a	pET-15b	vector	 at	 the	
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Nco1	and	BamH1	sites	in	E.	coli	Rosetta	2	(DE3)	cells	(Novagen).	A	poly-histidine	tag	followed	by	a	rhinovirus	(HRV)	3C	protease	cleavage	sequence	was	incorporated	into	 the	 coding	 sequence	 of	 the	 N-terminus	 of	 fusion	 proteins.	 The	 synthetic	constructs	were	produced	by	GenScript.	Transformed	cells	were	plated	on	LB	agar	containing	50	mg	ml-1	ampicillin	for	selection.	Colonies	were	harvested	and	grown		in	B	broth	(50	ug	mL-1	ampicillin)	to	an	OD600	of	0.6	in	1	L	cultures	at	310	K,	with	shaking	at	200	rpm.	The	cultures	were	then	incubated	on	ice	for	2	h	before	induction	with	0.4	mM	IPTG	and	incubation	overnight	at	293	K	with	shaking	at	180	rpm.		
 
Purification	The	cells	were	pelleted	by	centrifugation	at	9500	g	for	20min.	The	cell	pellets	were	resuspended	 in	 a	 buffer	 of	 150	 mM	 NaCl,	 1	 mM	MgCl,	 20	 mM	 Tris	 pH	 7.8	 and	protease	 inhibitor	 cocktail	 (cOmplete™,	 EDTA-free,	 Roche).	 The	 sample	 was	sonicated	for	5	min	with	5-second	intervals	(5	sec	on,	5	sec	off)	on	ice.	To	ensure	removal	of	DNA,	1	µL	of	non-specific	endonuclease	(Benzonase®	Nuclease,	sigma)	
Name	
FP-11	
FP-22	
CalFP-22	
CalFP-66	
Figure	13.	Fusion	protein	constructs.	Two	different	fusion	directionalities	were	tested.	Nomenclature	
used	was	FP	(fusion	protein)	when	IMPase	was	present	at	the	N-terminus	and	CalFP	when	Calbindin-
D28k	was	present	at	 the	N-terminus.	Three	different	 linker	 lengths	were	employed.	The	names	of	
each	construct	are	stated.				
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was	added	and	the	sample	 	 incubated	on	ice	for	a	further	10	min.	The	lysate	was	clarified	at	30,00	g	for	20	min.	The	supernatant	was	mixed	with	cobalt	affinity	resin	(Talon	metal-affinity	resin)	and	incubated	for	1	h	at	277	K	in	buffer.		The	resin	was	then	pelleted	by	centrifugation	at	9500	g	for	20	min.	Pellets	were	resuspended	in	a	buffer	of	150	mM	NaCl,	10	mM	imidazole	and	20	mM	Tris	pH	7.8.	The	flow-through	was	discarded	and	the	resin	was	washed	7	times	with	buffer.	The	fusion	proteins	were	eluted	using	5	washes	of	250	mM	imidazole.	HRV	C3	protease	was	added	to	cleave	 the	 His-Tag	 at	 a	 protease-to-target	 protein	 ratio	 of	 1:100	 (w/w)	 and	incubated	overnight	at	277	K.	The	cleaved	protein	was	purified	by	size	exclusion	chromatography	 on	 a	 Superdex	 G200	 in	 150	mM	NaCl	 and	 20	mM	 Tris	 pH	 7.8.	Typically,	>	8	mg	of	protein	was	obtained	from	each	1	L	of	culture.					Purification	 of	 calbindin-D28k	was	 performed	 as	 Noble	 et	 al.,	 2018	 and	 IMPase	purification	was	performed	as	Kraft	et	al.,	2018.		
SDS-page		1	μL	of	1	mg/ml	protein	was	mixed	with	6	μL	of	water	and	2.5	μL	of	NuPAGE™	LDS	Sample	Buffer.	The	samples	were	placed	in	a	dry	bath	at	95	°C	for	5	min	and	then	loaded	onto	a	NuPAGE	Novex	4-12%	bis-tris	gel.	The	gel	was	run	at	180	V	for	40	min	in	NuPAGE™	MES	SDS	Running	Buffer.	A	Mark12™	Unstained	Standard	was	used	as	the	 standard	 protein	 ladder.	 (Thermo	 Fisher,	 Ladder:	 LC5677,	 Gel:	 NP0322BOX,	Sample	buffer:	NP0007,	running	buffer:	NP0002).	Coomassie	blue	was	used	for	gel	staining	(InstantBluetm,	Expedeon).				
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Activity	Assay		A	 colorimetric	 phosphate	 quantification	 assay	 was	 used	 as	 an	 endpoint	 activity	assay.	15	nM	of	IMPase	or	fusion	protein	and	500	nM	of	calbindin-D28k	were	used	as	the	assay	protein	concentrations	in	a	final	volume	of	12	μL.	3	μL	of	substrate	was	added	to	produce	a	final	concentration	of	0.125	mM	Inositol	1-phosphate	in	a	final	reaction	volume	of	15	μL.	Reactions	were	incubated	at	37	℃	for	35	min,	with	80	%	humidity	 to	 prevent	 evaporation.	 Assay	 buffer	 was	 composed	 of	 20	 mM	 Tris	(pH7.8),	150	mM	NaCl	and	3	mM	MgCl.	The	addition	of	30	μL	of	BIOMOL®	green	(Enzo)	 reagent	 was	 used	 to	 stop	 the	 reaction.	 Plates	 were	 incubated	 at	 room	temperature	 for	 30	 min	 to	 allow	 the	 colour	 to	 fully	 develop.	 The	 assay	 was	performed	in	Clear	384	well	BRANDplates®	pureGrade™	F-bottom	plates	(BRAND).	Absorbance	was	measured	at	λ=	630	nm	using	a	PHERAstar	FS	plate	reader	from	BMG	Labtech.		
	
SAXS	SEC-SAXS	was	performed	at	the	B21	beamline	(Diamond	Light	Source	UK).	Fusion	proteins	 were	 dialyzed	 overnight	 using	 Pur-A-Lyzer™	 mini	 dialysis	 kit	 (Sigma-Aldrich	PURN60030-1KT)	 in	a	buffer	 consisting	of	20	mM	Tris	 (pH7.8),	150	mM	NaCl	and	3	mM	MgCl,	at	277K.	Using	an	HPLC	system,	45	μL	of	the	protein	samples	were	loaded	onto	a	Shodex	KW-403	column	at	the	concentrations	of	12,	10,	10	and	15.1	mg/ml	for	FP,	CAL-FP-66,	CAL-FP-22	and	FP-22	respectively.	X-ray	intensity	data	was	collected	as	the	eluent	moved	from	the	column	to	the	beam	at	a	flow	rate	of	 0.16	 ml/min.	 The	 intensity	 was	 plotted	 against	 its	 angular	 dependants	 q	(q=4πsinθ/λ).	The	system	operated	with	an	exposure	time	of	3	s	at	12.4	keV	(1Å)	using	a	PILATUS	2M	detector	located	at	a	distance	of	4	m	(Eiger	M4	detector	was	
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used	for	FP-22).	Data	were	analysed	using	the	SCÅTTER	and	ATSAS	program	suites	(Franke	et	al.,	2017;	Franke	and	Svergun,	2009;	Kozin	and	Svergun,	2001).	The	FoXS	web	 server	 was	 employed	 to	 compute	 the	 theoretical	 scattering	 profile	 using	 a	computational	docking	model	of	the	calbindin-IMPase	interaction	(Levi	et	al.,	2013)	for	 comparison	 with	 the	 experimental	 data	 (Schneidman-Duhovny	 et	 al.,	 2013,	2016).	The	SAXS	data,	analysis	and	models	have	been	deposited	in	the	Small	Angle	Scattering	Biological	Data	Bank	(Valentini	et	al.,	2015);	accession	codes:	TBC).	
	
Results		
Production	of	Fusion	Proteins	and	assessment	of	catalytic	activity	All	4	of	the	fusion	proteins	as	well	as	calbindin-D28k	and	IMPase	were	successfully	purified	to	a	high	level	of	purity.	FP-11	demonstrated	increased	relative	activity	of	200	 %,	 when	 compared	 to	 WT	 IMPase.	 	 FP-22,	 Cal-FP-22	 and	 Cal-FP-66	demonstrated	increased	relative	activity	of	approximately	400	%	when	compared	to	WT	IMPase.	IMPase	and	calbindin-D28k	together	demonstrated	a	relative	activity	of	600	%,	compared	to	WT	IMPase	alone	(Figure	14).		
 
Figure	8.	SDS	PAGE	gel	of	proteins	after	size	exclusion	chromatography	and	bar	graph	of	the	
results	from	the	activity	assay	with	the	standard	deviation	plotted.	Cal	sample	contains	both	
IMPase	and	Calbindin-D28k.	You	need	the	%	sign	on	the	axis	for	graph	on	the	right.	At	the	
moment	the	graph	and	the	text	above	don’t	match	up	well	
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Structural	Analysis	of	Fusion	Proteins	(SAXS)	The	Dmax	of	the	proteins	increases	with	increasing	linker	length,	with	values	of	162,	176,	175	and	218Å	obtained	for	FP-11,	FP-22,	Cal-FP-22	and	Cal-FP-66	respectively.	The	radius	of	gyration	(Rg)	also	increased	with	linker	length.	The	shortest,	FP-11,	displayed	a	Rg	of	46Å	and	the	longest,	Cal-FP-66,	displayed	a	Rg	of	57Å.	The	Porod	slope	for	all	four	fusion	proteins	was	q4	indicating	that	the	proteins	were	not	diffuse	and	unfolded	but	possess	a	more	globular	structure.	The	Kratky	plot,	normalized	to	Rg,	demonstrates	that	as	linker	length	increases	the	protein	becomes	more	flexible.	The	multiple	peaks	indicate	a	multi-domain	characteristic	of	the	fusion	proteins.	At	high	q	the	graph	approaches	the	baseline	indicating	a	folded	but	partially	flexible	structure	and	this	flexibility	increases	slightly	with	increasing	linker	length	(Figure	15B).	The	Distance	distribution	function	shows	multiple	peaks	indicating	the	multi-
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domain	characteristic	of	the	fusion	proteins	and	demonstrates	the	increase	in	Dmax	where	the	distribution	meets	the	X-axis	(figure	15C). 
Figure	9.	A)	Log10	SAXS	 intensity	versus	scattering	vector,	q.	Plotted	range	represents	 the	
positive	 only	 data	 within	 the	 specified	 q-range.	 B)	 Dimensionless	 Kratky	 plot.	 Crosshair	
marks	 the	 Guinier-Kratky	 point	 (1.7,	 1.1).	 C)	 Pair-distance,	 P(r),	 distribution	 function.	
Maximum	 dimension,	 dmax,	 is	 the	 largest	 non-negative	 value	 that	 supports	 a	 smooth	
distribution	function.	The	Guinier	fitting	for	all	data	sets	are	also	shown.	In	all	plots	Red	=	FP-
11,	Blue	=	FP-22,	Green	=	Cal-FP-22	Yellow	=	Cal-FP-66			Ab	initio	envelope	construction	from	SAXS	data	reveals	a	V-shaped	structure	of	the	fusion	proteins,	compared	to	the	in-silico	docking	model	that	displays	a	more	linear	confirmation.	The	experimental	intensities	deviate	significantly	from	the	calculated	model	intensities.	This	deviation	is	significant	at	both	high	q	to	low	q	regions	of	the	experimental	 intensities,	reflecting	differences	in	the	shape	and	size	of	the	fusion	proteins	(Figure	16).		
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Figure	10.	Ab	initio	envelope	construction	from	the	SAXS	data	of	individual	fusion	proteins.	
Bottom	right)	A	superimposition	of	the	in-silico	model	and	Cal-FP-22	fusion	protein	envelope.	
Bottom	 left)	 Log10	 SAXS	 intensity	 versus	 scattering	 vector	 q	 (Blue),	 The	 calculated	 foXS	
scattering	curve	of	the	in-silico	model	(Green).		
Discussion	The	use	of	 flexible	 linkers	 to	 stabilise	protein-protein	 interactions	has	 long	been	used	to	gain	insights	about	the	structure	and	function	of	protein	complexes	(Reddy	Chichili,	Kumar,	and	Sivaraman,	2013).	This	method	is	used	to	stabilize	transient,	lower	 affinity	 protein	 interactions,	 for	 example,	 TCR-peptide-MHC	 molecule	complexes	(Hennecke	and	Wiley,	2002;	Yin	et	al.,	2011;	Reddy	Chichili,	Kumar,	and	Sivaraman,	2013).	Here	we	used	this	method	to	study	the	interaction	between	the	calcium	 binding	 protein	 calbindin-D28k	 and	 the	 enzyme	 IMPase,	 a	 putative	therapeutic	target	of	lithium	in	bipolar	disorder.	This	interaction	has	a	relatively	low	affinity	(0.9	μM)	(Berggard,	Szczepankiewicz,	et	al.,	2002)	when	compared	to	other	
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protein-protein	interactions	that	often	exhibit	affinities	in	the	low	nanomolar	and	picomolar	range	with	large	protein	interfaces.	We	reasoned	that	the	production	of	fusion	proteins	of	IMPase	and	calbindin-D28k,	exploiting	the	use	of	linkers,	would	result	 in	 a	 more	 stable	 complex	 and	 allow	 for	 easier	 study	 of	 the	 interactions	between	these	proteins.			IMPase	has	remained	of	significant	therapeutic	 interest	since	the	development	of	the	inositol	depletion	hypothesis,	and	more	recently	in	the	induction	of	autophagy	(Allison	 and	 Stewart,	 1971;	 Harwood,	 2005;	 Sarkar	 et	 al.,	 2005).	 IMPase	 is	 an	extremely	stable	protein	and	 is	able	 to	withstand	high	 temperatures	 in	excess	of	80°C	(Kraft	et	al.,	2018).	Despite	the	interest	in	IMPase	as	a	therapeutic	target,	the	discovery	of	specific	inhibitors	that	are	effective	in	vivo	has	remained	elusive.	The	finding	that	calbindin-D28k	can	allosterically	increase	the	catalytic	activity	(Vmax)	of	 IMPase	 indicates	 that	 the	 enzyme	 could	 have	 significant	 structural	 plasticity.	Understanding	this	interaction	and	how	it	results	in	an	increase	in		catalytic	activity	of	IMPase	may	reveal	novel	therapeutic	approaches	to	IMPase	inhibition.	Unlike	a	traditional	 calcium	 sensor	 calbindin-D28k	 increases	 IMPase	 activity	 both	 in	 the	calcium	loaded	and	un-loaded	states.		Interestingly,	the	residues	of	Calbindin-D28k	involved	in	the	protein	interaction	are	also	involved	in	calcium	binding	(Berggard,	Szczepankiewicz,	 et	 al.,	 2002).	 The	 fusion	 proteins	 created	 here	 did	 not	 require	addition	of	calcium	in	order	to	observe	an	increase	in	catalytic	activity.				Several	 novel	 fusion	 proteins	 were	 produced	 using	 different	 linker	 lengths	 and	directionality.	Linker	length	exhibited	an	effect	on	the	activity	of	the	fusion	protein,	with	the	11	amino	acid	linker	(FP-11)	displaying	50%	less	catalytic	activity	than	the	
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other	 fusion	proteins	but	possessing	2	 times	more	 catalytic	 activity	 than	 IMPase	alone.	The	fusion	proteins	with	linker	lengths	of	22	amino	acids	or	more	displayed	the	same	catalytic	activity,	with	no	observable	effect	from	the	directionality	of	the	proteins.	None	of	the	fusion	proteins	showed	the	same	levels	of	catalytic	activity	that	were	observed	when	the	two	wild	type	proteins	were	mixed	together.	 	The	most	catalytically	active	fusion	proteins	displayed	a	relative	activity	of	4X	in	comparison	to	 calbindin-D28k	 and	 IMPase	 together,	 with	 a	 relative	 activity	 of	 6X	 when	compared	to	IMPase	alone.	In	the	activity	assay,	a	ratio	of	1:33	IMPase	to	calbindin-D28k	molecules	was	 present	 as	 compared	 to	 the	 1:1	 ratio	 present	 in	 the	 fusion	proteins	 assay.	 	One	hypothesis	 is	 that	 the	 flexible	 linker	may	 cause	 some	 steric	hindrance	to	the	protein	interaction	or	negatively	affect	the	structural	plasticity	of	the	 proteins	 compared	 to	 the	 wild	 type	 forms,	 thus	 explaining	 why	 the	 fusion	proteins	 lacked	 the	 full	 catalytic	 activity	 of	 the	wild	 type	 complex.	However,	 the	activity	of	the	longer	fusion	proteins	is	closer	to	the	activity	displayed	by	the	native	complex	 than	 that	 of	WT	 IMPase	 alone,	 rendering	 them	 a	 suitable	model	 of	 the	complex.			The	 SAXS	 data	 varies	 with	 varying	 linker	 length.	 The	 longest	 linker	 Cal-FP-66	displays	 the	 highest	 flexibility	 and	 possesses	 a	 structure	 distinct	 from	 the	 ideal	globular	system.	It	is	possible	that	there	may	be	increased	polydispersity	as	domains	from	 different	 fusion	 proteins	 form	 complexes.	 All	 of	 the	 proteins	 exhibit	 the	expected	multidomain	 topology	 in	 the	Kratky	 and	Distance	 distribution	 function	plots.	Both	Rg	and	Dmax	increase	with	linker	length.	Ab-initio	envelope	construction	produced	an	identical	structure	for	all	of	the	fusion	proteins	irrespective	of	linker	length	or	directionality.	The	envelopes	retain	a	V-shape	structure	compared	to	the	
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in-silico	model	of	the	complex.	The	V-shape	structure	provides	more	internal	space	for	the	protein	complex	to	occupy.	Comparison	of	the	SAXS	data	to	the	calculated	scattering	of	the	in-silico	model	(Levi	et	al.,	2013)	reveals	deviations	at	Low	and	High	q	regions.	This	is	due	to	a	difference	in	the	overall	shape	of	the	molecules	from	the	more	linear	in	silico	model	to	the	V-shaped	structure.	There	may	also	be	structural	changes	present	in	the	proteins	that	are	not	modelled	in	the	docking	simulations.	However,	only	large	conformational	changes	would	be	observable	using	the	SAXS	method	as	it	is	a	low-resolution	technique.			
Conclusion	The	 production	 of	 fusion	 proteins	 using	 flexible	 linkers	 can	 be	 successfully	employed	 to	 study	 the	 calbindin-IMPase	 interaction.	 The	 coupling	 of	 the	 two	proteins	via	a	flexible	linker	increases	the	catalytic	activity	of	IMPase.	Several	fusion	protein	isoforms	were	analyzed	by	SAXS	and	all	possess	a	V-shape	confirmation,	in	contrast	to	a	previous	 in-silico	model	that	predicted	a	 linear	conformation.	These	fusion	 protein	 constructs	 provide	 a	 model	 that	 could	 be	 exploited	 for	 detailed	analysis	of	the	Calbindin-IMPase	interaction	in	both	crystallographic	and	mutagenic	studies.			 	
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Exploration of a Novel Fragment Binding Site at the 
Homodimer Interface of Inositol Monophosphatase. 
	
	
James	W.	Noble,	Iain	J.	Day,	Mark	Roe,	Gary	J.	Tresadern	and	John	R.	Atack		
	
Abstract	Inositol	 Monophosphatase	 (IMPase)	 is	 an	 enzyme	 involved	 in	 the	 recycling	 of	inositol	 in	the	phosphatidylinositol	signalling	pathway.	 IMPase	catalyses	the	 final	de-phosphorylation	 of	 inositol-1-phosphate,	 which	 is	 then	 used	 to	 re-synthesise	phosphatidylinositol	 bisphosphate.	 IMPase	 has	 been	 proposed	 as	 a	 therapeutic	target	of	 lithium	in	bipolar	disorder	(Berridge,	Downes,	and	Hanley,	1982).	More	recently,	 it	 has	 been	 shown	 that	 inhibition	 of	 IMPase	 can	 stimulate	 autophagy	(Criollo	et	al.,	2007;	Motoi	et	al.,	2014;	Sarkar	et	al.,	2005).	Despite	the	therapeutic	potential	 of	 IMPase	 as	 a	 drug	 target,	 the	discovery	of	 specific	 inhibitors	 that	 are	effective	in	vivo	has	remained	elusive.	Therefore,	there	is	currently	a	lack	of	specific	pharmacological	tools	to	explore	the	inhibition	of	IMPase	in	vivo.	Here	we	present	a	novel	fragment	binding	site	at	the	homodimer	interface	of	IMPase.	Furthermore,	we	have	identified	five	chemical	fragments	that	bind	to	this	newly	identified	fragment	binding	 site.	 The	 fragments	 themselves	 do	 not	 inhibit	 IMPase,	 however	 point	mutations	 introduced	 at	 the	 dimer	 interface	 of	 the	 fragment-binding	 site	 have	resulted	 in	 inhibition	 of	 the	 enzyme.	 	 This	 inhibition	 was	 noted	 despite	 the	fragment-binding	site	being	a	distance	of	~26Å	away	from	the	active	site	of	IMPase.	These	 results	 demonstrate	 that	 the	 dynamics	 of	 the	 homodimer	 interface	 are	 a	critical	 feature	 for	 the	catalytic	activity	of	 IMPase.	The	 fragments	were	 identified	using	 a	 crystallographic	 soaking	 screen	 and	 binding	 was	 confirmed	 by	 NMR	spectroscopy.	This	novel	binding	site	is	the	first	fragment	binding	site	identified	for	
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IMPase	and	may	be	useful	starting	point	for	the	development	of	potent	inhibitors.	IMPase	exists	as	a	constitutive	homodimer	and	here	we	have	shown	that	changes	in	the	 properties	 of	 the	 homodimer	 interface	 inhibit	 IMPase	 activity.	 Therefore,	disruption	of	the	homodimer	could	be	a	useful	pharmacological	strategy	to	inhibit	the	enzyme.		
	
Introduction	IMPase	 is	 a	 metallophosphodiesterase	 enzyme.	 It	 is	 a	 highly	 conserved	homodimeric	 protein	 consisting	 of	 277	 amino	 acids	 per	 polypeptide	 chain.	 The	IMPase	structure	is	comprised	of	alternate	layers	of	α-helices	and	β-sheets,	forming	a	single	globular	tertiary	structure	that	is	thermally	stable	to	temperatures	in	excess	of	75°C	(Kraft	et	al.,	2018;	Bone,	Springer,	and	Atack,	1992;	McAllister	et	al.,	1992).	IMPase	requires	magnesium	for	its	activity	and	is	inhibited	by	other	ions,	such	as	calcium,	 that	 can	 replace	 the	magnesium	 in	 its	 active	 site	 (Atack	 et	 al.,	 1995b).	IMPase	 is	 involved	 in	the	phosphatidylinositol	signalling	cascade	that	 is	a	central	part	 of	 the	biology	of	 cell	 signalling.	The	 IP	 signalling	 cascade	 is	 initiated	by	 the	activation	of	a	G-protein	coupled	receptor	that	activates	PLC.	PLC	produces	IP3	by	the	hydrolysis	of	PIP2	in	the	 inner	 leaflet	of	 the	cell	membrane.	 IP3	then	defuses	through	 the	 cytosol	 and	 binds	 to	 receptors	 on	 the	 endoplasmic/sarcoplasmic	reticulum	and	induces	the	release	of	calcium	(Streb	et	al.,	1983,	Furuichi	et	al.,	1989,	Berridge,	1993).	DAG	remains	in	the	inner	leaflet	of	the	cell	membrane	and	binds	to	and	actives	PKC	(Newton,	1995).	Subsequently,	IP3	is	recycled	back	to	inositol	by	a	series	of	enzymes,	of	which	IMPase	catalyzes	the	last	step.			
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Lithium	 is	employed	 in	 the	 treatment	of	bipolar	disorder	and	 inhibits	 IMPase	by	preventing	 the	 release	 of	 the	 phosphate	 after	 the	 hydrolysis	 of	 myo-inositol-1-phosphate	 (IP1)	 (Lu	 et	 al.,	 2012).	 It	 was	 demonstrated	 that	 lithium	 decreases	inositol	levels	in	vivo	(Allison	&	Stewart,	1971)	and	these	data	later	resulted	in	the	formation	of	the	inositol	depletion	hypothesis	of	lithium’s	efficacy	in	the	treatment	of	 bipolar	 disorder	 (Berridge,	 Downes,	 and	 Hanley,	 1982).	 Recently,	 it	 has	 been	shown	 that	 the	 inhibition	 of	 IMPase	 can	 induce	 autophagy	 and	 the	 subsequent	clearance	of	peptides	involved	in	the	pathogenesis	of	neurodegenerative	diseases	in	
vitro	 (Motoi	 et	 al.,	 2014;	 Sarkar	 et	 al.,	 2005).	 These	 studies	 inhibited	 IMPase	pharmacologically	 using	 the	 compounds	 lithium	 and	 L-690,330	 and	 generated	significant	 interest.	 This	 is	 the	 second	 method	 identified	 to	 induce	 autophagy	pharmacologically,	the	first	being	with	the	use	of	rapamycin	that	induces	autophagy	via	the	inhibition	of	mTOR	(Criollo	et	al.,	2007).		
Despite	IMPase	being	of	therapeutic	interest	since	the	1970s,	no	specific	inhibitors	have	been	discovered	that	are	effective	in	vivo.	In	the	1990s,	efforts	were	made	by	the	 pharmaceutical	 company	 Merck	 to	 design	 an	 inhibitor	 based	 on	 the	 IP1	substrate.	They	synthesized	methylenebisphosphonic	acid	derivatives	of	 IP1	 that	were	non-hydrolysable	(Baker	et	al.,	1990).	These	inhibitors	possessed	high	affinity.	L690-330	 (IC50	 0.2	 µM)	 was	 the	 most	 promising	 and	 later	 co-crystallized	 with	IMPase	 (Atack	 et	 al.,	 1993,	 Kraft	 et	 al.,	 2018).	 As	 IMPase	 has	 an	 extremely	hydrophilic	active	site	in	order	to	bind	to	its	hydrophilic	substrate	IP1	and	ion	co-factors	 (Ferruz	 et	 al.,	 2016),	 the	 L690-330	 inhibitor	 also	 contains	 hydrophilic	phosphate	 groups.	 Highly	 hydrophilic	 inhibitors	 lack	 cell	 and	 central	 nervous	
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system	 (CNS)	 penetration.	 Attempts	 were	 made	 to	 produce	 a	tetrapivaloyloxymethyl	ester	prodrug	 that	would	be	 less	 charged	however,	 these	later	 failed	 in	 vivo	 due	 to	 solubility	 issues	 (Atack	 et	 al.,	 1994).	 More	 recently,	 a	compound	 known	 as	 Ebselen,	 that	 binds	 covalently	 to	 cysteine	 residues,	 was	identified	 as	 an	 inhibitor	 of	 IMPase	 (Singh	 et	 al.,	 2013).	 Although	 less	 potent	(Ebselen	IC50	1.5	µM)	than	L690-330,	it	was	more	hydrophobic	than	the	previously	identified	substrate	mimetic.	However,	its	small	molecular	weight	(Mr	=	274)	and	intrinsic	 reactivity	make	 it	 prone	 to	 polypharmacology.	 The	 selenium-containing	ring	 in	 Ebselen	 is	 similar	 to	 an	 isothiazolone	 and	molecules	with	 this	 group	 are	known	as	a	Pan-Assay	Interference	Compound	(PAINS).	These	compounds	are	often	avoided	by	medicinal	chemists	due	to	the	challenges	of	engineering	specificity	into	intrinsically	reactive	molecules	(Baell	and	Nissink,	2018).		
Here	 we	 aim	 to	 identify	 novel	 binding	 sites	 and	 chemical	 matter	 that	 could	 be	employed	 to	 develop	 a	 new	 class	 of	 IMPase	 inhibitors.	 To	 achieve	 this	 a	crystallographic	fragment	screen	was	performed.	This	allowed	the	detection	of	very	weakly	binding	fragments	that	may	not	directly	inhibit	IMPase	and	therefore	may	not	be	identified	by	the	use	of	other	techniques.	The	discovery	that	IMPase	can	be	allosterically	 modulated	 by	 protein-protein	 interaction	 with	 calbindin-D28K	(Berggard	 et	 al.,	 2002)	 has	 increased	 the	 interest	 in	 this	 approach.	 This	 finding	indicates	that	there	may	be	significant	structural	plasticity	within	IMPase	that	could	be	exploited	pharmacologically.			
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Methods		
	
Protein	expression	and	Purification	IMPase	was	produced	as	described	by	Kraft	et	al.,	2018.	During	purification	of	the	mutant	IMPase	enzymes	the	heat	purification	step	was	omitted.		
Apo-IMPase	Crystallisation	Crystallographic	 screens	 were	 performed	 using	 an	 IMPase	 concentration	 of	 40	mg/mL,	at	a	temperature	of	293K,	in	a	buffer	composed	of	20	mM	Tris	(pH	7.8),	150	mM	 NaCl	 and	 1	 mM	 MgCl.	 Crystallization	 was	 performed	 in	 MRC	 2-well	crystallization	plates	(Swissci),	using	a	reservoir	volume	of	50	μl	and	a	drop	volume	of	0.4	μl	consisting	of	a	1:1	ratio	of	precipitant	solution	and	protein	solution.	The	Crystal	Phoenix	crystallography	dispenser	(Art	Robbins	Instruments)	was	used	to	prepare	 crystal	 plates.	 IMPase	 binds	 phosphate	 and	 sulphate,	 therefore	 buffer	components	 that	 contain	 those	 groups,	 such	 as	 HEPES,	 were	 avoided.	 The	precipitant	 screen	 Structural	 Screen	 1	 &	 2	 (Molecular	 Dimensions)	 yielded	 Apo	crystals	 with	 conditions	 of	 0.2	 M	 Sodium	 acetate	 trihydrate,	 0.1	 M	 sodium	cacodylate	 (pH	6.5)	 and	30	%	w/v	PEG	8000.	 The	 crystal	 condition	 and	protein	concentration	 were	 further	 empirically	 optimised	 to	 0.19	 M	 Sodium	 acetate	trihydrate,	0.1	M	sodium	cacodylate	(pH	6.5),	28.5	%	w/v	PEG	8000,	3.5	mM	MgCl	and	incubation	at	277K	using	9.4	mg/mL	IMPase.			
Fragment	Screen	Crystals	 were	 soaked	 with	 the	 addition	 of	 a	 fragment	 precipitant	 solution	 with	either	 3	 fragments	 at	 a	 concentration	 of	 13.3	 mM	 or	 with	 one	 fragment	 at	 a	
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concentration	 of	 4	 mM	 and	 a	 final	 DMSO	 concentration	 of	 40%.	 Crystals	 were	incubated	 for	 1	 hour	 at	 293K	 prior	 to	 the	 addition	 of	 1.2	 μl	 of	 the	 fragment	precipitant	solution	mix.	The	crystals	were	incubated	for	a	further	hour	and	then	picked	 and	 plunge	 cryo-cooled	 in	 liquid	 nitrogen.	 Around	 400	 fragments	 were	screened	successfully.	The	data	were	processed	using	the	fast_dp	data	possessing	pipeline	 followed	 by	 the	 difference	 map	 pipeline	 DIMPLE.	 Fragments	 were	identified	using	Pan-Dataset	Density	Analysis	(PanDDA)	(Pearce	et	al.,	2017).	Five	fragments	of	 interest	were	 identified	and	 those	hits	 in	 “cocktail”	were	confirmed	individually.			
Activity	Assay		The	assay	was	performed	in	384	clear	flat-bottomed	plates	(BRAND),	30	nM	IMPase	was	incubated	with	0.125	mM	Myo-inositol	1-monophosphate	(Enzo)	for	45	min	at	37	 °C	and	80	%	humidity	 to	prevent	evaporation.	The	assay	was	performed	 in	a	buffer	of	20	mM	Tris-HCL	(pH	7.8),	150	mM	NaCl,	4	mM	MgCl	and	1	mM	EGTA	in	a	total	reaction	volume	of	15	μl.	The	assay	was	stopped	by	the	addition	of	30	μl	of	BIOMOL	Green	reagent	(Enzo)	and	was	incubated	at	room	temperature	for	a	further	30	min.	The	absorbance	at	630	nm	was	analysed	on	a	PHERAstar	BMG	plate	reader.			
NMR	STD		Concentrations	of	50	µm	of	IMPase	and	5	mM	of	fragments	were	used	for	all	STD	NMR	experiments	and	these	were	performed	in	a	solution	of	150	mM	NaCl,	20	mM	Tris	(pH	7.8-HCL),	10	%	DMSO	and	10	%	D2O.	STD	experiments	were	recorded	with	a	saturation	time	of	0.5	s,	with	on	and	off-resonance	irradiation	applied	at	-0.5	and	30	ppm	respectively	(Mayer	and	Meyer,	2001). 
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Mutant	IMPase	Crystallisation	Crystallisation	 of	 both	 IMPase	 mutant	 proteins	 was	 performed	 in	 MRC	 2-well	crystallisation	plates	(Swissci)	using	a	reservoir	volume	of	50	μl	and	a	drop	volume	of	0.4	μl,	consisting	of	a	1:1	ratio	of	the	precipitant	solution	and	protein	solution.	The	crystallisation	of	the	methionine	179	mutant	was	performed	at	a	concentration	of	12	mg/ml	in	a	buffer	of	20	mM	Tris	(pH	7.8),	150	mM	NaCl,	5	mM	MgCl,	and	a	precipitant	solution	of	0.19	M	Sodium	acetate	trihydrate,	0.1	M	sodium	cacodylate	(pH	 6.5),	 28.5	 %	 w/v	 PEG	 8000,	 3.5	 mM	 MgCl	 and	 with	 incubation	 at	 293K.	Crystallographic	 screens	 of	 the	 leucine	176	mutant	 IMPase	were	performed	 in	 a	buffer	of	20	mM	Tris	(pH	7.8),	150	mM	NaCl,	5	mM	MgCl	using	a	60	mg/ml	protein	concentration.	 The	 best	 diffracting	 crystals	 were	 identified	 from	 BCS	 high	throughput	percipient	Screen	(molecular	dimensions,	MD1-105)	well	C3	containing	0.15	M	NaCl	and	28	%	v/v	PEG	smear	medium.		
Mutant	Crystal	Data	Collection	and	Analysis	Data	were	collected	at	100	K	using	30	%	glycerol	as	a	cryoprotectant,	on	the	I03	beamline	(Diamond	Light	Source)	as	set	up	on	the	03/05/2018	for	mutant	L176W.	1200	 images	were	collected	with	a	ω	oscillation	of	0.15	and	an	exposure	 time	of	0.020	s	per	 image	at	a	wavelength	of	0.976	Å,	Beam	size	of	50	μm	by	20	μm	and	transmission	of	72.12	%.	Diffraction-	 intensity	data	were	indexed,	 integrated	and	scaled	using	the	autoPROC	toolbox	(Vonrhein	et	al.,	2011).	Molecular	replacement	was	performed	with	Phaser	(McCoy	et	al.,	2007),	with	initial	refinement	in	refmac5	(Murshudov	et	al.,	2011)	and	Coot	in	the	CCP4	suite	of	programs.	The	final	model	was	completed	in	Coot	(Emsley	et	al.,	2010)	and	the	model	was	refined	with	BUSTER	
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v.2.10.2.	Data	were	collected	at	100	K	with	30	%	glycerol	as	a	cryoprotectant,	on	Rigaku	copper	rotating	anode	X-ray	generator	and	a	CCD	detector,	at	a	wavelength	of	1.54	Å	and	a	detector	distance	of	58.8	mm	for	mutant	M179W.		
Results		
Apo-IMPase	Crystallisation	The	 crystals	 obtained	 using	 the	 initial	 crystallisation	 conditions	 formed	 shards.	These	were	very	thin,	fragile	and	not	suitable	for	high	throughput	picking	of	crystals.	The	crystals	diffracted	well,	to	a	resolution	of	1.5	Å.	The	optimisation	screen	yielded	rod-shaped	 crystals	 and	 these	 improved	when	 grown	 at	 a	 lower	 temperature	 of	277K	(Figure	17).			
	
Figure	11.	Crystal	optimisation	experiment.	The	far-left	image	depicts	the	crystals	obtained	
from	 the	 initial	 crystal	 screen.	 The	 center	 image	 depicts	 the	 crystals	 formed	 in	 the	
optimisation	matrix.	The	image	on	the	far	right	depicts	the	crystals	formed	in	the	optimised	
crystal	conditions	at	a	lower	temperature.			
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Crystallographic	Fragment	Screen		Five	fragments	were	identified	that	bound	to	IMPase	(Figure	18)	(Crystallographic		
Figure	18.	Structures	of	the	five	molecules	identified	in	the	fragment	screen.	UOS-
19245	contains	the	reactive	isothiazolone	ring	that	binds	non-specifically	to	the	
cysteine	residues	in	IMPase.	
	
	 77	
Table	3	Crystallographic	statistics	for	all	crystals	presented	here.	Values	in	parentheses	are	for	
the	highest	shell.	
Data	set	 JNJ-
1360983	
JNJ-
661349	
UOS-
19226	
UOS-
19278	
UOS-
19245	
L176W	 M179W	
Beamline	 IO4-1	(DLS)	 IO4-1	(DLS)	 IO3	(DLS)	 IO3	(DLS)	 IO4-1	(DLS)	 IO3	(DLS)	 RIGAKU	
Unit-cell	
parameters	
	 	 	 	 	 	 	
A	(Å)	 55.29	 51.76	 51.81	 58.63	 56.20	 54.91	 84.99	
B	(Å)	 76.37	 75.76	 76.10	 74.87	 77.09	 75.95	 84.99	
C	(Å)	 57.42	 71.76	 71.95	 58.93	 57.91	 57.03	 152.16	
Α	(°)	 90	 90	 90	 90	 90	 90	 90	
Β	(°)	 95.03	 105.98	 105.98	 99.12	 95.08	 94.46	 90	
γ	(°)	 90	 90	 90	 90	 90	 90	 120	
	
Space	group	
P	1	21	1	 P	1	21	1	 P	1	21	1	 P	1	21	1	 P	1	21	1	 P1	21	1	 P	31	2	1	
Wavelength	 0.9159	 0.9159	 0.9762	 0.9762	 0.9282	 0.9762	 1.54056	
Resolution	
range	
22.31-1.53	(1.53-1.56)	
51.01-1.62	(1.62	–	1.65)	 69-.17	–	1.61	(1.61	–	1.64)	
46.23	–	1.59	(1.59-1.62)	
31.75	–	1.95	(1.95-	1.98)	
44.41	–	1.58(1.58-1.73)	 28.12-	2.20	(2.20-	2.27)	
No.	of	
observations	
361733	(18338)	 336084	(16400)	 440015	(16442)	 445449	(21047)	 153364	(7790)	 113103	(5796)	 304132	(21292)	
No.	of	unique	
observations	
71599	(3566)	 66934	(3213)	 69596	(3265)	 68641	(3199)	 35807	(1762)	 34094	(1705)	 33010	(2804)	
Completeness	 99.9	(99.9)	 98.7	(95.6)	 99.7	(94.3)	 99.8	(94.8)	 99.6	(98.8)	 92.4	(72.7)	 99.9	(99.8)	
Multiplicity	 5.1	(5.1)	 5.0	(5.1)	 6.3	(5.0)	 6.5	(6.6)	 4.3	(4.4)	 3.3	(3.4)	 9.2	(7.6)	
Anomalous	
completeness	
96.9	(97.5)	 96.5	(93.8)	 99.5	(94.5)	 99.6	(94.7)	 95.3	(95.7)	 86.5	(70.2)	 99.6	(95.6)	
Anomalous	
multiplicity	
2.6	(2.6)	 2.6	(2.6)	 3.2	(2.6)	 3.3	(3.3)	 2.2	(2.3)	 1.7	(1.8)	 4.7	(3.8)	
Rmeas	 0.072	(1.752)	 0.111	(1.753)	 0.116	(1.988)	 0.102	(1.789)	 0.082	(1.132)	 0.096	(0.876)	 0.186	(0.684)	
CC1/2	 1.00	(0.5)	 1.0	(0.5)	 1.0	(0.5)	 1.0	(0.7)	 1.0	(0.7)	 1.0	(0.5)	 0.99	(0.942)	
I/σ(i)	 11.8	(1.1)	 9.3	(1.1)	 8.4	(1.0)	 8.2	(1.0)	 12.6	(1.5)	 9.3	(1.6)	 10.2	(3.8)	
Refinement	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	 BUSTER	v.2.10.3	
Resolution	
range	(Å)	
22.34-1.53	 51.01-1.62	 1.80	–	47.02	 23.24-1.59	 26.62-1.95	 21.14-1.58	 28.12-	2.20	
Rcryst	 0.195	 0.187	 0.183	 0.192	 0.194	 0.190	 0.231	
Rfree	 0.217	 0.213	 0.221	 0.203	 0.23	 0.237	 0.265	
No.	of	protein	
atoms	
4308	 4132	 4178	 4311	 3998	 3915	 4071	
No.	of	ligand	
atoms	
14	 18	 18	 27	 42	 0	 31	
No.	of	solvent	
atoms	
269	 423	 501	 354	 224	 113	 263	
Mean	B	factor	
(Å2)	
34.15	 21.03	 21.70	 32.15	 41.22	 27.19	 26.05	
R.m.s.d.,	bond	
lengths	(Å)	
0.01	 0.01	 0.01	 0.01	 0.01	 0.01	 0.009	
R.m.s.d.,	bond	
angles	(°)	
1.12	 1.12	 1.09	 1.09	 1.06	 1.12	 1.20	
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	statistics	for	all	crystals	are	shown	in	Table	3).		Fragment	UOS-19245	bound	to	multiple	sites	on	IMPase	by	the	covalent	binding	to	cysteine	residues.		The	isothiazolinone	ring	opens	and	forms	a	disulfide	bond	with	cysteine	 residues	 in	 an	 unspecific	manner	 (Supplementary	 Figure	 3).	 Fragments	UOS-19226,	 UOS-19278,	 JNJ-661349	 and	 JNJ-1360983	 bound	 to	 IMPase	 at	 the	homodimer	interface	of	the	protein.	These	fragments	are	bound	by	cation	π-stacking	interactions	to	arginine	173	of	IMPase	(Figure	19).	
	
	
Figure	12.	A)	Fragment	 JNJ-661349	bound	to	 the	homodimer	 interface	of	 IMPase,	with	 the	
cation-	π-stacking	interaction	denoted	by	a	green	dotted	line	and	a	hydrogen	bind	denoted	by	
a	yellow	dotted	line.	B)	The	same	as	(A)	with	the	addition	of	the	surface	of	the	fragment	shown	
by	a	blue	mesh,	the	aliphatic	ring	of	JNJ-661349	buried	in	the	homodimer	interface.	C)	The	
superimposition	of	all	the	crystal	structures.	All	of	the	halogen	containing	fragments	have	the	
halogen	buried	in	the	homodimer	interface.				
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Saturation	Transfer	Difference	(STD)	NMR	Fragments	 that	 were	 commercially	 available	 (UOS-19226,	 UOS-19278	 and	 JNJ-1360983)	were	assessed	for	IMPase	binding	using	STD	NMR.	Negative	peaks	were	observed	 for	 all	 fragments	 that	 were	 identified	 in	 the	 crystallography	 screen	confirming	binding	to	IMPase	(Figure	20).	
	
Figure	13.	The	STD	NMR	spectra	for	JNJ-1360983	(A),	UOS-19278	(B)	and	UOS-19226	(C).	The	
top	blue	spectra	are	the	off-resonance	spectra	and	the	bottom	burgundy	spectra	are	the	STD-
spectra.	The	negative	peaks	indicate	a	positive	result	of	fragment	binding.	
	
IMPase	Mutants	IMPase	exists	as	a	constitutive	homodimer,	therefore,	disruption	of	the	homodimer	interface	by	a	drug	molecule	could	be	a	strategy	to	identify	novel	inhibitors.	In	order	test	if	disruption	of	this	dimer	interface	at	the	fragment-binding	site	would	lead	to	inhibition,	mutants	were	developed	in	an	attempt	to	simulate	a	hydrophobic	drug	
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molecule	 penetrating	 the	 homodimer	 interface.	 Tryptophan	 is	 a	 hydrophobic	residue	that	is	close	to	the	size	of	a	small	drug	molecule.	Tryptophan	mutants	were	produces	and	exhibited	a	decrease	in	catalytic	activity	compared	to	the	wild	type	IMPase.	The	methionine	to	tryptophan	mutant	had	a	relative	activity	of	48	%	and	the	leucine	to	tryptophan	mutant	had	a	relative	activity	of	27	%	compared	to	WT	IMPase.	 Crystallisation	 and	 structural	 analysis	 revealed	 no	 significant	 structural	change	 in	 the	 protein	 structure	 of	 these	mutants	 compared	 to	wild	 type	 IMPase	(Figure	21).			
	
	
Figure	14.	 (A)	shows	a	measure	of	 the	distance	 from	a	 fragment	bound	 to	 the	homodimer	
interface	 to	 an	 active	 site	 residue	 of	 IMPase.	 (B)	 the	 residues	mutated	 (176	 and	 179)	 to	
tryptophan.	 These	 residues	 are	 directly	 under	 the	 fragment	 binding	 site.	 (C)	 The	 crystal	
structures	 of	 the	 lysine	 to	 tryptophan	mutant	 (GREEN)	 superimposed	 on	 to	 the	wild	 type	
IMPase	 (BLUE).	 (D)	 The	 relative	 activities	 the	 IMPase	 mutants	 normalized	 to	 wild	 type	
IMPase.		
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Discussion	IMPase	is	a	phosphodiesterase	enzyme	that	is	involved	in	the	IP	signalling	cascade.	IP3	 is	 produced	 by	 the	 hydrolysis	 of	 phosphatidylinositol	 4,5-bisphosphate.	 IP3	then	defuses	through	the	cytosol	to	channels	on	the	ER	or	SR	inducing	the	release	of	calcium	(Majerus,	1992;	Harwood,	2005).	This	cascade	 is	 involved	in	a	myriad	of	physiological	 functions	 and	 is	 one	 of	 the	 key-signalling	 cascades	 in	 cell	 biology.	IMPase	 is	 involved	 in	 the	 homeostasis	 of	 this	 pathway,	 catalysing	 the	 final	dephosphorylation	of	the	inositol	1-phosphate	(ref).			IMPase	has	been	of	therapeutic	interest	since	the	formation	of	the	inositol	depletion	hypothesis	of	lithium’s	therapeutic	efficacy	in	the	treatment	of	bipolar	disorder	and	more	recently	due	to	the	induction	of	autophagy	by	its	inhibition	(Berridge,	Downes,	and	 Hanley,	 1982;	 Sarkar	 et	 al.,	 2005).	 Despite	 repeated	 attempts	 to	 find	 drug	candidates,	 effective	 inhibitors	 of	 IMPase	 have	 remained	 allusive.	 The	 inhibitory	molecules	 that	 have	 been	 discovered	 to	 date	 have	 possessed	 undesirable	physicochemical	 properties,	 such	 as	 being	 reactive	 or	 too	 hydrophilic	 or	hydrophobic	 (Atack	 et	 al.,	 1993;	 Atack	 et	 al.,	 1994;	 Singh	 et	 al.,	 2013).	 Here	 a	crystallographic	soaking	screen	was	employed	to	identify	novel	binding	sites	and	chemical	matter.	This	method	allows	for	the	detection	of	the	binding	of	fragments	with	 low	affinity,	 that	may	not	be	 identified	by	 the	use	of	other	 techniques.	Five	binding	 fragments	were	 identified	yielding	a	hit	rate	of	around	1-2	%.	A	reactive	isothiazolinone	 fragment	 (UOS-19245)	 was	 identified;	 this	 chemical	 group	 is	identical	to	that	found	in	Ebselen,	with	a	sulphur	substituted	for	selenium	in	Ebselen	(Singh	et	al.,	2013).		
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We	have	produced	the	first	crystal	structure	of	an	isothiazolinone	bound	to	IMPase.	Electron	 density	 of	 the	 fragment	 can	 be	 observed	 around	 the	 majority	 of	 the	cytosine	residues	in	the	IMPase	crystal	structure,	demonstrating	that	there	is	not	a	specific	binding	site	 for	 this	 fragment.	Four	 fragments	were	 found	 to	bind	 to	 the	homodimer	interface	at	the	same	binding	site.	This	was	the	only	specific	fragment	binding	site	identified	in	the	screen,	suggesting	this	is	the	most	tractable	fragment	binding	site	on	IMPase.	The	interaction	at	this	binding	site	is	produced	by	a	cation	π	clamping	mechanism,	with	 arginine	 173	 from	 both	 polypeptide	 chains	 clamping	around	both	sides	of	the	aromatic	rings	in	the	fragments.	These	arginine	residues	change	conformation	and	stabilize	around	the	fragments.	This	fragment	binding	site	is	26	Å	away	from	the	active	site	of	IMPase,	therefore,	inhibition	conferred	from	this	site	 would	 likely	 be	 allosteric	 as	 opposed	 to	 competitive	 inhibition	 with	 the	substrate.	IP1	is	a	hydrophilic	substrate	and	an	inhibitor	that	binds	to	the	active	site	would	 likely	 mimic	 these	 properties	 and	 would	 result	 in	 poor	 cell	 penetration.	Therefore,	 inhibition	via	an	allosteric	site	may	enable	compounds	with	 improved	physicochemical	 properties	 to	 be	 developed.	 There	 are	 two	 options	 when	undertaking	 drug	 discovery	 at	 sites	 that	 are	 distant	 from	 the	 active	 site	 of	 an	enzyme;	 firstly,	 to	 explore	 any	 potential	 allosteric	 activity	 of	 the	 site,	 or	 the	development	 of	 a	 high	 affinity	 compound	 that	 can	 be	 developed	 into	 a	 PROTAC	leading	to	in	situ	degradation	of	the	target	(Toure	and	Crews,	2016).		In	order	to	test	the	hypothesis	that	disruption	of	the	homodimer	interface	of	IMPase	would	result	in	loss	of	catalytic	activity,	two	mutants	were	developed	that	attempted	to	 simulate	 a	 drug	 molecule	 penetrating	 the	 homodimer	 interface.	 L176W	 and	M179W	 aimed	 to	 simulate	 hydrophobic	 drug	 molecules	 by	 either	 shallowly	 or	
	 83	
deeply	penetrating	the	homodimer	interface	under	the	fragment	banding	site.	Both	mutants	reduced	the	activity	of	IMPase,	with	the	L176W	(shallow)	mutant	having	the	largest	reduction	in	activity	at	73%	compared	to	the	52%	reduction	in	activity	for	 the	deeply	penetrating	M179W	(deep)	mutant	 (figure	21D).	 Interestingly	 the	crystal	structures	of	both	mutants	revealed	no	difference	in	the	secondary,	tertiary	and	 quaternary	 protein	 structure	 of	 the	 mutants	 when	 compared	 to	 wild	 type	IMPase.	This	indicates	that	the	dynamics	of	this	homodimer	interface	are	important	for	the	catalytic	cycle	of	IMPase,	as	small	changes	in	the	properties	of	the	interface	can	reduce	and	inhibit	IMPase	activity.	This	can	be	achieved	without	a	full	disruption	of	 the	 homodimer	 interface,	 which	 would	 be	 challenging	 for	 a	 small	 molecule	inhibitor.			Proteins	 forming	 inside	a	crystal	 lattice	are	 in	a	very	different	environment	 from	being	in	solution.	Crystallographic	contacts	may	act	as	a	binding	site	or	 influence	fragment	binding.	Therefore,	it	is	necessary	to	confirm	the	binding	of	fragments	to	protein	 in	 solution.	 This	was	 performed	 using	 STD	NMR,	 a	 technique	where	 the	protein	is	in	its	native	form	in	solution.	All	commercially	available	fragments	were	tested,	and	binding	was	detected	providing	confirmation	of	binding	of	the	fragments	to	IMPase	in	solution.			
Conclusion		In	 this	 paper,	 we	 describe	 identification	 of	 a	 novel	 fragment-binding	 site	 at	 the	homodimer	 interface	 of	 IMPase.	 This	 is	 the	 first	 example	 shown	of	 non-covalent	binding	 of	 drug-like	 molecules	 to	 IMPase,	 outside	 of	 its	 active	 site.	 Four	 non-covalently	 binding	 fragments	 were	 identified	 using	 a	 combination	 of	 NMR	 and	
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crystallographic	screening.	Using	site-directed	mutagenesis,	we	have	shown	that	the	properties	 of	 the	 homodimer	 interface	 directly	 under	 the	 fragment	 binding	 are	important	 for	 catalytic	 activity	 of	 the	 enzyme,	 despite	 the	 fragment	 binding	 site	being	 located	approximately	26	Å	away	 from	 the	 active	 site.	The	 introduction	of	mutated	 residues	 did	 not	 disrupt	 the	 structure	 of	 IMPase,	 or	 the	 homodimer	interface,	 suggesting	 that	 the	 physiochemical	 properties	 of	 the	 interface	 are	important	in	the	catalytic	cycle	of	IMPase. 	 	
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Isothiazolinone Inhibition of Inositol Monophosphatase  	
James	W.	Noble,	Gary	J.	Tresadern	and	John	R.	Atack		
	
Abstract	Inositol	monophosphates	(IMPase)	is	an	enzyme	of	significant	therapeutic	interest	both	in	the	treatment	of	bipolar	disorder	and	the	induction	of	autophagy.		In	2013,	Singh	et	al.,	reported	the	discovery	of	a	novel	safe	IMPase	inhibitor.	The	inhibitor	they	 identified,	 named	 Ebselen,	 is	 a	 covalent	 inhibitor.	 Ebselen	 possesses	 a	selenium-nitrogen	single	bond	that	breaks	open	and	covalently	bonds	to	cysteine	residues	in	proteins.	Here	we	aim	to	explore	this	group	of	reactive	compounds	by	screening	67	isothiazolinone	containing	compounds	for	inhibitory	activity	against	IMPase.	From	this	screen,	we	identified	4	compounds		as	inhibitors	of	IMPase.	These	inhibitors	exhibit	IC50	values	in	the	low	micromolar	range	similar	to	that	reported	for	 ebselen	 (1.5	 μM).	 The	 compounds	 were	 identified	 using	 an	 enzymatic	colorimetric	phosphate	quantification	assay	and	binding	was	confirmed	by	thermal	denaturation	assay.	The	identified	compounds	displayed	the	biochemical	properties	of	 irreversible	 inhibitors	 as	 inhibition	 was	 time-dependent,	 and	 dilution	 of	 the	compounds	does	not	decrease	 level	of	 inhibition.	The	compounds	identified	from	this	screen	all	possess	similar	chemical	structures.	Here	we	present	a	new	class	of	irreversible	 IMPase	 inhibitors	 that	 are	 significantly	 chemically	 different	 from	ebselen.	This	novel	group	of	inhibitors	could	be	further	developed	to	create	potent	IMPase	inhibitors.					
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Introduction		IMPase	has	been	of	therapeutic	interest	since	the	formation	of	the	inositol	depletion	hypothesis	of	the	efficacy	of	lithium	in	the	treatment	of	bipolar	disorder	(Berridge,	Downes,	and	Hanley,	1982).	IMPase	is	a	homodimeric	enzyme	that	is	involved	in	the	homeostasis	 of	 the	 IP3	 signalling	 cascade.	 IMPase	 catalyses	 the	 final	dephosphorylation	of	the	inositol	sugar	from	Inositol	1-Phosphate	(ref).	The	inositol	depletion	hypothesis	was	initially	based	on	the	discovery	that	lithium	treatment	in	rats	causes	a	30	%	reduction	 in	 the	 inositol	concentration	 in	 the	cerebral	cortex.		This	was	 later	 combined	with	 the	discovery	 that	 lithium	treatment	 increases	 the	concentration	of	 Inositol	1-Phosphate	 in	 the	 cerebral	 cortex	 (Allison	et	al.,	 1976,	Allison	 &	 Stewart,	 1971).	 Furthermore,	 IMPase	 purified	 from	 rats	 and	 bovine	sources	was	 shown	 to	be	 sensitive	 to	 lithium	 (Naccarato	et	 al.,	 1974,	Hallcher	&	Sherman,	 1980,	 Harwood,	 2005).	 Lithium	 is	 a	 small	 ion	 and	 exhibits	polypharmacology.	Therefore,	identifying	exactly	how	lithium	exerts	its	therapeutic	efficacy	is	challenging,	due	to	the	wide	range	of	enzymes	lithium	inhibits.	As	lithium	exhibits	 polypharmacology,	 it	 also	 possesses	 significant	 toxicity	 with	 a	 small	therapeutic	 window	 that	 requires	 continual	 monitoring	 of	 lithium	 plasma	concentration	(Timmer	&	Sands,	1999).			It	has	recently	been	shown	that	inhibition	of	IMPase	can	induce	autophagy	and	that	this	 effect	 can	 be	 reversed	 by	 the	 addition	 of	 free	 inositol	 in	 vitro	 (Sarkar	 et	 al.,	2005).	 Subsequent	 studies	 have	 described	 the	 clearance	 of	 peptides	 induced	 by	lithium	and	more	specific	IMPase	inhibitors	(L-690,330).	Studies	have	described	the	clearance	 of	 mutated	 Huntington	 in	 Huntington’s	 disease,	 α-synuclein	 in	
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Parkinson's	disease	and	phosphorylated	tau	 in	Alzheimer’s	disease	(Criollo	et	al.,	2007;	Motoi	et	al.,	2014).			The	development	of	specific	inhibitors	of	IMPase	would	facilitate	an	evaluation	of	the	 inositol	 depletion	 hypothesis	 and	 enable	 evaluation	 of	 the	 role	 of	 IMPase	inhibition	in	autophagy	 in	vivo.	Attempts	at	developing	specific	 IMPase	 inhibitors	have	 ended	 in	 varying	 degrees	 of	 success	 and	 failure.	 In	 the	 1990s,	 the	pharmaceutical	 company	 Merck	 developed	 an	 array	 of	 inhibitors	 based	 on	 the	Inositol	 1-Phosphate	 substrates	 of	 IMPase.	Merck	 developed	 a	 non-hydrolysable	substrate	mimetic	by	synthesising	methylenebisphosphonic	acid	derivatives	(Baker	
et	al.,	1990).	The	compounds	developed	had	a	high	potency	and	of	these	L-690,330	was	the	most	promising,	with	an	IC50	of	0.2	μM	in	vitro	(Atack	et	al.,	1993).	L-690,330	possesses	two	negatively	charged	phosphate	groups	which	results	in	poor	cell	and	central	nervous	 system	penetration.	Attempts	 to	 create	a	prodrug	 that	would	be	metabolised	in	the	cells	to	form	the	active	L-690,330	molecule		failed	as	the	prodrug	precipitated	 at	 the	 site	 of	 administration	 in	 vivo	 (Atack	et	 al.,	 1994).	Despite	 the	failure	of	L-690,330	as	an	effective	treatment,	it	is	still	useful	in	vitro	as	a	specific	IMPase	inhibitor.		A	screen	of	the	US	National	Institutes	of	Health	Clinical	Compound	Collection	(NCC)	of	bioactive	compounds	(450	compounds)	identified	the	compound	Ebselen	as	an	inhibitor	of	IMPase	(Singh	et	al.,	2013).	Ebselen	contains	a	pan	assay	interference	(PAINS)	 group	 known	 as	 an	 isoselenazolone.	 This	 chemical	 group	 contains	 a	Selenium-Nitrogen	single	bond	that	can	break	open	and	form	covalent	bonds	with	cysteine	residues	in	proteins	(Baell	&	Nissink,	2018).		Here	we	explore	this	reactive	
	 89	
chemical	group	further	by	screening	67	isothiazolinone	containing	compounds	from	the	Janssen	Pharmaceutical	library	for	the	inhibition	of	IMPase.	We	have	substituted	the	selenium	for	sulphur		as	this	is	an	element	found	more	commonly	in	commercial	drugs	 (Feng	 et	 al.,	 2016).	 The	 aim	 is	 to	discover	potential	 new	 inhibitors	 and	 to	evaluate	 if	 the	 isothiazolinone	chemical	group	has	the	potential	 to	be	engineered	into	a	high-affinity	specific	inhibitor.	 	
Methods		
Colorimetric	Phosphate	Quantitation	Assay	67	 unique	 compounds	 and	 fragments	 were	 tested	 for	 inhibitory	 activity	 with	respect	to	IMPase.	Each	compound	was	screened	in	triplicate	at	a	concentration	of	266.4	μM	with	an	enzyme	concentration	of	0.8	µg/µL	in	an	assay	buffer	of	20	mM	Tris	(pH	7.8)	150	mM	NaCl	3	mM	MgCl	and	5%	DMSO	and	a	final	Myo-inositol	1-monophosphate	(Enzo)	concentration	of	0.125	mM.	Compounds	were	added	to	the	reaction	10	min	before	the	substrate.	The	biochemical	assay	for	phosphate	detection	was	 performed	 in	 Clear	 384	 well	 BRANDplates®	 pureGrade™	 F-bottom	 plates	(BRAND).	 Plates	 were	 incubated	 at	 37	 ℃	 and	 80	 %	 humidity	 (to	 inhibit	evaporation)	for	40	min.	Post	incubation	30	µl	of	BIOMOL®	green	(Enzo)reagent	was	added	and	plates	were	incubated	at	room	temperature	for	30	min	to	allow	the	colour	to	develop.	Measurement	of	absorbance	at	λ=	630	nm	was	performed	in	a	PHERAstar	 FS	 plate	 reader	 from	 BMG	 Labtech.	 The	 screen	 was	 performed	 in	triplicate	 and	 hits	 were	 defined	 as	 showing	 inhibition	 of	 IMPase	 >	 30	 %.	 To	determine	the	IC50	values	of	the	compounds,	a	dilution	series	for	each	compound	series	was	prepared.		40	nM	of	IMPase	was	incubated	with	the	compound	for	20	min	before	the	addition	of	3	μl	substrate.		The	assay	was	then	performed	as	stated	above.	
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Thermal	Denaturation	assay	Thermal	Denaturation	studies	of	 IMPase	were	performed	with	 inhibitors	using	a	LightCycler	 480	 II	 (Roche)	 in	 Multiwell	 96	 well	 white	 plates	 (Roche).	 A	 10	 x	concentration	of	SYPRO®	Orange	Protein	Gel	Stain	(Sigma	S5692)	was	used	as	the	detection	reagent.	6	μM	of	IMPase	was	diluted	in	a	buffer	of	0.5	%	DMSO,	Tris	20	mM	(pH	7.8),	150	mM	NaCl	and	3	mM	MgCl	with	varying	compound	concentrations.	Thermal	 Denaturation	 was	 monitored	 through	 a	 temperature	 range	 of	 20-95℃	with	an	integration	time	set	to	1	sec	and	fluorescence	measured	with	excitation	at	465	nm	and	emission	at	580	nm.		
Biochemical	Inhibitor	Mechanistic	Assays	
	
Inhibition	Time	Course		40	nM	IMPase	was	incubated	with	a	dilution	series	of	JNJ-6157935	in	a	buffer	of	20	mM	Tris	 (pH	7.8),	150	mM	NaCl,	3	mM	MgCl	and	5%	DMSO.	The	 incubation	was	performed	at	room	temperature	at	time	points	of	10,	20	and	30	min.	The	assay	was	performed	 as	 described	 in	 Colorimetric	 Phosphate	 Quantitation	 Assay	 method	section.			
Inhibition	Dilution	Assay	1.35	mg/mL	IMPase	was	incubated	with	500	µM	JNJ-6157935	in	a	buffer	of	20	mM	Tris	(pH	7.8),	150	mM	NaCl,	3	mM	MgCl	and	5	%	DMSO.	Incubation	was	performed	at	room	temperature	for	30	min	and	the	sample	was	then	diluted	to	44.7	nM	IMPase	(giving	 a	 final	 compound	 concentration	 on	 500nM).	 3	 μl	 of	 Myo-inositol	 1-
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monophosphate	(Enzo)	substrate	was	then	added	resulting	in	a	final	concentration	of	0.125	mM.	IMPase	alone	and	IMPase	with	100	μM	or	500	μM	JNJ-6157935	were	treated	identically	to	the	dilution	sample.	The	assay	was	then	performed	as	stated	in	the	Colorimetric	Phosphate	Quantitation	Assay	method.		
	
Results	
Compound	Screen	The	compound	screen	yielded	a	skewed	distribution	of	the	activity	of	IMPase,	with	most	compounds	registering	an	increase	in	activity.	Four	wells	produced	inhibitory	results	identifying	three	novel	compounds.	 	These	compounds	were	distinct	from	the	 normal	 distribution	 of	 IMPase	 activity	 and	 separated	 from	 the	 skewed	distribution	of	 the	screen	 (Figure	22A).	 IC50	 curves	were	 then	determined	 for	all	three	“HIT”	compounds.	The	IC50	values	recorded	for	JNJ6150704,	JNJ6157935	and	JNJ6170374	were	2.4,	7.9	and	18.1	μM	respectively	(Figure	22B).		
 
Figure	15.	A)	A	histogram	of	 the	screening	data.	Red	 is	 IMPase	without	compound,	blue	 is	
IMPase	with	compound.	The	screen	was	performed	in	single	point	with	the	mean	average	of	
three	replicates	used	in	the	histogram.	B)	IC50	curves	with	the	mean	and	standard	deviation	
for	 each	 data	 point	 plotted	 (n=3).	 Red	 is	 JNJ6150704	 with	 an	 IC50	 of	 2.4μM,	 Green	 is	
JNJ6157935	with	an	IC50	of	7.9	μM,	Blue	is	JNJ6170374	with	an	IC50	of	18.1	μM.			
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Compounds	and	SAR	The	three	hit	compounds	came	from	the	same	sub-group	of	compounds	within	the	screen	as	these	compounds	all	have	a	similar	chemical	structure	(Figure	23).	
 
Figure	16.	The	chemical	structure	of	the	group	of	the	compounds	that	exhibited	inhibition	of	
IMPase.	The	top	three	compounds	were	identified	in	the	initial	screen	as	IMPase	inhibitors.	
The	bottom	two	compounds	were	from	the	same	class	and	were	not	identified	in	the	initial	
screen	as	inhibitors.	The	reactive	isothiazolone	ring	of	the	molecule	is	placed	at	the	bottom	of	
the	molecules.	There	 were	 two	 compounds	 (JNJ-24792362	 and	 JNJ-29379833)	 present	 in	 the	compound	library	that	came	from	the	same	class	of	compounds	as	the	identified	hits,	
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however	they	did	not	demonstrate	inhibitory	properties	in	the	initial	screen.	IC50	curves	 were	 performed	 with	 the	 compounds	 of	 similar	 structure	 to	 assess	 any	potential	activity.	Compound	JNJ-24792362	demonstrated	limited	activity	with	only	one	 atom	substituted	when	 compared	 to	 JNJ-6157935,	 identified	 from	 the	 initial	screen.	 A	 pyridyl	 group	 replaced	 the	 phenyl	 causing	 a	 significant	 reduction	 in	activity.	 Replacing	 the	 phenyl	 ring	 for	 a	 morpholine	 group	 (JNJ-29379833)	eliminated	all	activity	of	the	compounds	(Figure	24).		
 
Figure	17.	IC50	curves	with	the	mean	and	standard	deviation	for	each	data	point	plotted	(n=3).	
JNJ6157935	 (green)	 with	 an	 IC50	 of	 7.9	 μM,	 the	 SAR	 compound	 JNJ24792362	 (lilac)	 and	
JNJ29379833	(yellow).	Compound	JNJ24792362	did	exhibit	some	inhibitory	activity	but	no	
inhibitory	activity	was	observed	for	JNJ29379833.		
	
Thermal	Denaturation	Orthogonal	testing	Shifts	were	observed	in	the	thermal	denaturation	curves	of	IMPase	in	the	presence	of	all	of	 the	compounds	 that	demonstrated	 inhibitory	activity	 in	 the	Colorimetric	Phosphate	 Quantitation	 Assay.	 Shifts	 were	 concentration	 dependent	 and	
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demonstrated	a	similar	morphology	to	the	previously	described	inhibitor	Ebselen.	Due	to	the	additional	hydrophobic	aromatic	ring,	at	high	concentrations	compound	JNJ-6150704	induced	the	fluorescence	of	the	dye	in	the	assay	(Figure	25).			
 
Figure	 18.	 Thermal	 denaturation	 curves	 of	 IMPase	 with	 different	 concentrations	 of	
compound.	 D)	 is	 the	 positive	 control	 compound	 ebselen.	 Three	 replicate	 thermal	
denaturation	curves	were	performed,	with	one	representative	curve	shown	here.			
	
Mechanism	of	action	A	dilution	and	a	time-course	assay	were	used	to	determine	if	the	class	of	compounds	were	 covalent	non-reversible	 inhibitors.	The	activity	of	 IMPase	was	not	 restored	when	JNJ6157935	was	diluted	to	below	its	maximum	inhibitory	concentration	to	500	nM.	This	is	indicative	of	non-reversible	inhibition.	The	activity	of	this	compound	was	both	time	and	concentration	dependent.	At	the	10	min	time	point,	full	inhibition	
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of	IMPase	was	not	reached.	At	20	and	30	min,	full	inhibition	of	IMPase	was	reached	with	no	statistical	difference	in	the	IC50	value	of	these	respective	curves	(Figure	26).			
 
Figure	19.	A)	IC50	dilution	series	of	JNJ6157935	incubated	for	different	amounts	of	time	with	
IMPase	 before	 the	 addition	 of	 the	 substrate.	 Green	30mins	 (n=3),	 red	 20mins	 (n=3),	 blue	
10mins	(n=2).	The	mean	and	standard	deviation	for	each	data	point	is	plotted.	B)	A	bar	graph	
of	relative	activity	normalized	to	IMPase	activity.	The	mean	and	standard	deviation	for	each	
data	bar	is	plotted.					
	
Discussion		IMPase	is	a	protein	that	is	of	significant	therapeutic	interest	both	with	regards	to	Bipolar	disorder	and	more	recently	the	induction	of	autophagy	induced	by	IMPase	inhibition	(Berridge,	Downes,	and	Hanley,	1982;	Sarkar	et	al.,	2005).	Despite	this	interest,	specific	inhibitors	that	are	effective	in	vivo	have	remained	elusive.	Ebselen	was	 found	 to	 inhibit	 IMPase	 from	 a	 screen	 of	 the	 National	 Institutes	 of	 Health	Clinical	Collection.	This	is	a	chemical	library	of	small	molecules	that	have	a	history	of	use	in	clinical	trials	and	therefore	a	proven	track	record	for	safety	(Singh	et	al.,	2013).	 Ebselen	 has	 an	 isoselenazolone	 ring.	 The	 Selenium-Nitrogen	 single	 bond	breaks	 open	 and	 covalently	 modifies	 IMPase	 giving	 rise	 to	 ebselen’s	 inhibitory	efficacy.	 Here	 for	 the	 first	 time,	 we	 employ	 a	 specifically	 curated	 isothiazolone	screen	 of	 67	 unique	 compounds	 to	 explore	 this	 chemical	 group,	 substituting	 the	
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isoselenazolone	of	ebselen	has	for	an	isothiazolone	ring.	This	replaces	the	selenium	for	 sulphur	and	has	 two	benefits.	 Firstly,	 although	 selenium	 is	 an	essential	 trace	element	it	has	known	toxicity	issues,	can	cause	selenosis	and	therefore	should	be	avoided	 in	 drug	 molecules	 (Olson,	 1986).	 Secondly,	 sulphur	 is	 a	 more	 common	element	 in	 drugs	 and	 therefore	 allows	 the	 screening	 of	 a	 wider	 selection	 of	compounds	(Feng	et	al.,	2016).	Both	isoselenazolone	and	isothiazolone	possess	the	same	ability	to	break	open	and	form	bonds	with	cysteine	residues	in	proteins	(King	
et	al.,	2009;	Pacula	et	al.,	2017).			Four	compounds	were	identified	in	the	preliminary	screen	as	exhibiting	inhibitory	activity.	The	compounds	identified	all	belonged	to	the	same	structural	subset	of	the	compound	library.	Examination	of	the	identified	molecules	reveals	that	the	long	tail	region,	 on	 the	 opposite	 side	 of	 the	 molecule	 from	 the	 isothiazolone	 ring,	 is	particularly	important	for	determining	the	activity	of	the	compound.	Exploring	this	region	with	medicinal	chemistry	could	be	a	strategy	for	further	optimisation	of	the	activity	of	the	compounds.			Shifts	in	thermal	denaturation	curves	of	IMPase	were	used	as	an	orthogonal	assay	to	confirm	binding	of	the	hit	molecules.	Thermal	denaturation	was	selected	as	an	orthogonal	 assay	 as	 unlike	 the	 Colorimetric	 Phosphate	 Quantitation	 Assay	 that	measures	catalytic	activity,	the	thermal	denaturation	assay	measures	the	change	in	the	stability	of	IMPase	due	to	the	molecules	binding	to	the	target.	Both	assays	use	the	protein	 in	 its	 native	 state	 and	do	not	 require	 any	protein	modifications.	 The	shifts	observed	in	the	thermal	denaturation	curve	of	IMPase	upon	treatment	with	each	of	the	four	hit	compounds	were	large	and	concentration	dependent.	The	shifts	
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were	similar	in	morphology	to	that	obtained	by	the	compound	ebselen,	which	was	used	as	a	positive	control.				The	novel	molecules	described	in	this	paper	are	irreversible	binders,	as	inhibition	is	 observed	 after	dilution	of	 the	 compounds	 from	maximal	 inhibitory	 range.	The	compounds	also	require	longer	incubation	times	in	order	to	inhibit	IMPase,	a	trait	often	 observed	 with	 irreversible	 covalent	 binders.	 This	 result	 suggests	 that	 the	reactivity	 of	 the	 isothiazolone	 ring	 is	 required	 for	 the	 inhibition	 of	 IMPase	 and	inhibition	is	not	achieved	solely	via	binding	of	the	compound	on	its	own.		After	the	identification	of	ebselen	as	an	inhibitor	of	IMPase,	no	further	exploration	in	order	to	discover	further	covalent	inhibitors	has	been	performed.	By	performing	a	limited	screen	of	67	molecules,	we	have	identified	three	IMPase	inhibitors	with	a	potency	 range	 of	 between	 2.4-18	 μM,	 similar	 to	 that	 of	 ebselen	 (ebselen	 1.5	 μM	(Singh	et	al,.	2013).	Reactive	groups	on	potential	drug	molecules	imparts	an	intrinsic	polypharmacology.	 Therefore,	 compounds	 with	 these	 groups	 must	 possess	 very	high	affinity	to	the	protein	target,	 in	order	to	counteract	this	property.	From	this	study,	we	have	observed	that	a	range	of	chemical	matter	other	than	ebselen	that	can	inhibit	 IMPase	 with	 the	 use	 of	 isothiazolone	 reactive	 groups.	 However,	 only	 3	compounds	 from	 the	 isothiazolone	 compound	 library	were	 potent	 enough	 to	 be	detected	in	the	initial	screen,	equating	to	a	hit	rate	of	4.5	%.	This	demonstrates	that	the	reactive	isothiazolone	group	alone	is	not	responsible	for	the	inhibitory	activity	observed	in	these	compounds,	and	opens	up	the	possibility	of	engineering	potency	and	specificity	through	medical	chemistry	efforts.		
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Conclusion	We	have	identified	a	new	group	of	IMPase	inhibitors	by	screening	compounds	that	share	a	similar	chemical	group	to	the	previously	 identified	inhibitor	ebselen.	The	inhibitors	described	were	identified	using	a	biochemical	enzymatic	primary	assay	and	a	biophysical	orthogonal	assay.	67	isothiazolone	compounds	were	selected	for	screening,	based	on	the		known	mechanism	for	activity	of	the	isoselenazolone	ring	in	 ebselen	 .	 Although,	 this	 group	 is	 known	 to	 be	 reactive,	 only	 a	 small	 subset	 of	molecules	 screened	 (4.5	 %)	 displayed	 inhibitory	 activity	 at	 the	 screening	concentration	tested,		suggesting	that	potency	could	be	engineered	into	the	reactive	chemical	 backbone.	 The	 compounds	 identified	 exhibit	 IC50	 values	 in	 the	 low	micromolar	range.	As	these	compounds	possess	reactive	chemical	groups	they	are	likely	 to	 possess	 innate	 polypharmacology.	 Therefore,	 significant	 medicinal	chemistry	 efforts	 must	 be	 undertaken	 in	 order	 to	 optimise	 the	 affinity	 of	 these	compounds.		
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	 100	Final	Discussion		The	primary	aims	of	this	thesis	were	to	gain	new	insights	into	the	calbindin-IMPase	interaction	and	to	develop	novel	pharmacology	of	IMPase.	The	project	was	split	into	two	 branches:	 The	 biological	 allosteric	 modulation	 of	 IMPase	 and	 the	pharmacological	allosteric	modulation	of	 IMPase.	The	approach	for	 the	biological	branch	 was	 to	 first	 obtain	 a	 crystal	 structure	 of	 the	 IMPase	 binding	 partner	calbindin-D28k	 and	 to	 subsequently	 develop	 a	 series	 of	 calbindin-IMPase	 fusion	proteins	in	order	to	stabilize	and	study	the	protein	complex.	The	approach	for	the	pharmacological	 branch	 was	 to	 firstly	 discover	 new	 fragment	 binding	 sites	 of	IMPase	by	performing	a	crystallographic	fragment	screen,	and	secondly	to	identify	new	covalent	inhibitors	of	IMPase	based	on	the	ebselen	reactive	group.			Calbindin-D28k	 is	 a	 highly	 expressed	 calcium	 binding	 protein	 with	 expression	reaching	 up	 to	 1.5	 %	 of	 total	 protein	 content	 in	 certain	 sections	 of	 the	 brain	(Christakos,	 Gabrielides,	 and	 Rhoten,	 1989).	 In	 this	 thesis,	 the	 focus	 centred	 on	calbindin-D28k	due	to	its	ability	to	increase	the	activity	of	IMPase,	by	as	much	as	250	fold	(Berggard,	Szczepankiewicz,	et	al.,	2002).	This	finding	indicates	that	there	may	 be	 significant	 structural	 plasticity	 in	 IMPase	 that	 could	 be	 exploited	pharmacologically.	 However,	 few	 studies	 have	 been	 published	 that	 study	 the	protein	 interaction	 in	 vitro,	 aside	 from	 simple	 biochemical	 analysis	 and	 in	 silico	modelling	(Levi	et	al.,	2013).	Despite	 the	 involvement	of	calbindin-D28k	 in	many	physiological	processes	and	the	interest	in	its	therapeutic	potential,	an	X-ray	crystal	structure	of	the	protein	has	remained	elusive.	Past	attempts	to	obtain	a	structure	have	 failed	 to	 yield	 results	 (Zhang	 et	 al.,	 2008).	 Calcium	buffering	 proteins	 have	
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historically	remained	a	challenge	for	structural	analysis	by	crystallography,	due	to	their	composition	of	small	flexible	domains,	resulting	in	intrinsic	flexibility	that	can	inhibit	crystallisation.	Due	to	the	flexible	nature	of	calcium	binding	protein,	NMR	is	often	the	method	of	choice	to	obtain	structural	models	of	proteins	of	this	type.	The	calbindin-D28k	NMR	model	was	reported	in	2006.	At	the	time,	calbindin-D28k	(30	kDa)	was	one	of	the	largest	protein	structures	resolved	by	this	technique	(Kojetin	et	
al.,	2006).	NMR	is	often	employed	to	explore	the	structure	of	smaller	proteins	<35	kDa	and	there	are	two	main	reasons	for	this.	Firstly,	larger	molecules	tumble	more	slowly	in	solution	and	exhibit	shorter	NMR	signal	relaxation	times.	Secondly,	larger	proteins	result	in	more	complex	spectra	and	the	signals	from	nuclei	overlap,	which	makes	analysis	increasingly	difficult	with	increasing	size	(Yu,	1999).			After	purification	of	human	calbindin-D28k,	the	SAXS	data	obtained	in	this	thesis	was	distinct	 from	 that	predicted	by	 the	NMR	model.	Therefore,	we	attempted	 to	obtain	a	crystal	structure	of	calbindin-D28k.	Production	of	a		X-ray	crystal	structure	allowed	the	direct	visualisation	of	the	calcium	ions	bound	by	calbindin-D28k,	thus	providing	 new	 insights	 compared	 to	 the	 existing	 NMR	 spectroscopy	 data.	 The	crystal	 structure	 obtained	 exhibited	 significant	 variations	 from	 that	 of	 the	 NMR	model.	 The	 crystal	 structure	 was	 less	 condensed	 compared	 to	 the	 NMR	 model.	Furthermore,		the	SAXS	data	was	more	aligned	to	the	crystal	structure	than	the	NMR	model,	indicating	that	the	crystal	structure	is	a	better	model	of	calbindin-D28k	in	solution.	Both	of	these	findings	are	somewhat	counterintuitive	as	it	has	been	argued	that	NMR	models	are	more	biologically	 relevant	 (ref),	as	proteins	are	 in	solution	when	NMR	spectra	are	obtained.	Packing	proteins	 into	a	crystal	 lattice	can	cause	
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structural	 deviations	 from	 the	 protein	 structure	 in	 solution	 (Garbuzynskiy	et	 al,.	2005).				The	proposed	new	model	of	the	structure	of	calbindin-D28k	at	high	resolution	(1.51	A)	provides	an	improved	understanding	of	calbindin-D28k	structure	and	suggests	mechanisms	by	which	calbindin-D28k	may	bind	to	IMPase.	Thus,	these	additional	structural	insights	of	calbindin-D28k	have	revealed	that	the	N-terminal	region	of	the	protein	is	particularly	flexible.	This	is	the	region	of	calbindin-D28k	that	is	implicated	in	 the	 protein-protein	 interactions	 of	 the	 protein	 (ref).	Mutagenesis	 of	 aspartate	residues	 24	 and	 26	 to	 alanine	 inhibit	 the	 potentiation	 of	 IMPase	 activity	 by	calbindin-D28k	 and	 a	 peptide	 fragment	 of	 Ran-binding	 protein	M	 has	 also	 been	shown	to	interact	with	this	region	of	the	protein	(Lutz	et	al,.	2003).	This	intrinsic	flexibility	 most	 likely	 frustrated	 the	 attempts	 to	 obtain	 a	 crystal	 structure	 of	calbindin-D28k	in	the	past.	However,	this	flexibility	could	be	an	important	property	of	calbindin-D28k	 that	enables	 it	 to	make	protein	 interactions.	Disorder-to-order	transitions	upon	binding	is	a	well-documented	property	of	specific	protein-protein	interactions	 (Mendoza-Espinosa	 et	 al.,	 2009).	 The	 flexibility	 of	 the	 N-terminal	should	be	considered	in	any	future	modelling	of	the	Calbindin-IMPase	interaction.			To	gain	further	insight	into	the	calbindin-IMPase	interaction,	the	creation	of	fusion	proteins	using	a	flexible	amino	acid	linker	was	explored.	This	technique	of	fusing	protein	binding	partners	together	has	previously	been	used	to	obtain	structures	of	protein	 complexes	 and	 to	 study	 protein	 complexes	 (Reddy	 Chichili,	 Kumar,	 and	Sivaraman,	 2013).	 Here,	 I	 successfully	 designed	 fusion	 protein	 constructs	 that	demonstrate	improved	catalytic	activity	compared	to	IMPase	alone.	This	is	the	first	
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time	 that	 the	 activating	 effect	 of	 calbindin-D28k	 on	 IMPase	 has	 been	 confirmed.	SAXS	 data	 collected	 from	 the	 fusion	 protein	 constructs	 predict	 a	 flexible	 multi-domain	protein.	Ab	initio	reconstruction	of	the	proteins	from	the	SAXS	data	revealed	a	 V-shaped	 protein	 complex	 that	 differed	 from	 the	 structure	 predicted	 by	 a	published	docking	model	of	the	interaction	(ref).	The	low-resolution	structures	of	the	fusion	protein	are	longer	than	those	predicted	by	the	in-silico	docking	model.	All	four	fusion	proteins	possess	the	same	globular	structure,	irrespective	of	differences	in	 the	 activity	 due	 to	 the	 fusion	 protein	 linker	 directionality	 and	 linker	 length.	Attempts	to	crystallise	the	fusion	proteins	to	obtain	a	high-resolution	structure	of	the	protein	complex	have	failed	to	yield	positive	results.	As	the	fusion	proteins	are	larger	 than	 130	 kDa	 they	 are	 at	 the	 lower	 limit	 of	 resolution	 by	 cryo-EM,	 and	therefore	it	may	be	possible	to	obtain	a	structure	using	this	method	in	the	future.	A	high-resolution	structure	of	these	fusion	proteins	may	enable	an	understanding	of	how	calbindin-D28k	exhibits	its	activating	effect	on	IMPase.	An	understanding	of	the	structural	 plasticity	 of	 IMPase	 may	 then	 be	 informative	 in	 the	 design	 of	 novel	therapeutics.	In	summary,	regarding	the	biological	allosteric	modulation	of	IMPase,	we	have	demonstrated	that	IMPase	binds	to	a	flexible	region	of	calbindin-D28k.	We	have	 reported	 a	 high	 resolution	 model	 of	 calbindin-D28k	 and	 shown	 that	 the	Calbindin-IMPase	 interaction	 forms	 a	 V-shaped	 complex	 that	 deviates	 from	previous	 predictions.	 	 We	 have	 developed	 a	 set	 of	 fusion	 proteins	 that	 can	 be	employed	to	obtain	high	resolution	structures	of	the	complex.		IMPase	has	been	of	 significant	 therapeutic	 interest	 since	 the	development	of	 the	inositol	depletion	hypothesis	in	the	1970/80s	and	more	recently	in	the	induction	of	autophagy	(Berridge,	Downes,	and	Hanley,	1982;	Sarkar	et	al.,	2005).	Despite	this,	
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the	 identification	of	novel	 inhibitors	and	chemical	matter	have	been	frustratingly	sparse.	 In	 this	 thesis,	 I	 aimed	 to	 increase	 the	chemical	 space	 in	which	 to	explore	IMPase	pharmacology.	Prior	to	this	work,	non-covalent	binding	sites	outside	of	the	active	 site	 had	 not	 been	 identified.	 IMPase	 has	 recently	 been	 shown	 to	 have	allosteric	properties	in	relation	to	its	interaction	with	calbindin-D28k	(ref	or	refer	to	your	work),	indicating	that	binding	sites	outside	of	the	active	sites	can	modulate	IMPase	 activity.	 Therefore,	 I	 aimed	 to	 identify	 novel	 fragment	 binding	 sites	 of	IMPase.	To	achieve	 this,	 I	 elected	 to	perform	a	 crystallographic	 fragment	 screen.	Screening	by	 the	use	 of	 crystallography	 techniques	 is	 sensitive	 and	may	 identify	fragments	 that	bind	with	 low	affinity	 that	are	otherwise	missed	by	 less	sensitive	techniques.	Here	I	identified	a	novel,	non-covalent	binding	site	26Å	outside	of	the	active	site	of	IMPase.	The	fragment	screen	identified	four	novel	fragments	that	bind	at	 the	 homodimer	 interface	 of	 IMPase.	 IMPase	 is	 a	 constitutive	 homodimer	 in	solution.	Therefore,	disruption	of	the	homodimer	interface	may	present	a	possible	pharmacological	mechanism	for	the	inhibition	of	IMPase.			To	 test	 this	 hypothesis,	 I	 generated	mutant	 proteins	 harbouring	mutations	 sited	directly	 below	 the	 fragment	 binding	 site	 of	 IMPase.	 These	 mutations	 aimed	 to	simulate	 hydrophobic	 compounds	 penetrating	 the	 homodimer	 interface.	 These	mutations	 resulted	 in	 a	 significant	 reduction	 of	 IMPase	 activity.	 Crystallographic	analysis	 of	 the	mutant	 proteins	 revealed	 that	 the	mutations	 did	 not	 disrupt	 the	structure	of	IMPase.	This	suggests	that	a	change	in	dynamics	of	the	protein	interface	is	responsible	for	the	inhibitory	effect	of	these	mutations.	The	fragment	binding	site	could	be	exploited	further	by	the	development	of	a	PROTAC.	If	medicinal	chemistry	efforts	 can	design	higher	affinity	 fragments	and	 link	 to	a	E3	 ligase	 substrate,	 the	
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resulting	 compound	 would	 trigger	 the	 in	 situ	 degradation	 of	 IMPase	 via	 the	proteasomal	degradation	pathway.		The	absence	of	IMPase	is	predicted	to	result	in	the	same	biological	effect	as	the	direct	inhibition	of	IMPase.			In	2013	it	was	reported	that	the	molecule	ebselen	could	inhibit	IMPase	(Singh	et	al.,	2013).	Ebselen	possesses	a	reactive	chemical	group	termed	isoselenazolone.	Here	we	aimed	to	screen	compounds	with	a	similar	reactive	group	termed	isothiazolone	due	 to	 substitution	of	 a	 selenium	atom	 for	 sulphur.	 Selenium	possesses	 intrinsic	toxicity	 which	 can	 cause	 selenosis,	 and	 therefore	 should	 be	 avoided	 in	 drug	molecules	(Olson,	1986).	Secondly,	sulphur	is	a	more	common	element	in	medicinal	chemistry	 and	 therefore	 would	 facilitate	 screening	 of	 a	 wider	 selection	 of	compounds	(Feng	et	al.,	2016).	The	compounds	identified	in	this	screen	were	all	of	a	similar	structure	and	inhibited	IMPase	via	an	irreversible	mechanism.	These	novel	IMPase	 inhibitors	 exhibit	 similar	 activity	 to	 that	 reported	 for	 ebselen	but	have	a	significantly	different	chemical	structure.	They	represent	a	novel	group	of	inhibitors	however,	 they	 likely	 inhibit	 IMPase	 via	 the	 same	mechanism	 as	 ebselen.	 I	 have	significantly	expanded	the	number	of	known	compounds	that	 irreversibly	 inhibit	IMPase.		This	provides	a	larger	group	of	compounds	to	be	studied	and	may	lead	to	the	production	of	potent	specific	covalent	inhibitors.		
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Conclusion		I	have	significantly	added	to	the	understanding	of	the	Calbindin-IMPase	interaction	by	obtaining	the	first	crystal	structure	of	calbindin-D28K	and	by	the	development	of	novel	 Calbindin-IMPase	 fusion	 proteins.	 The	 crystal	 structure	 of	 calbindin-D28k	revealed	 a	 flexible	 N-terminus	 and	 provided	 the	 first	 direct	 visualization	 of	 the	calcium	binding	sites.		The	Calbindin-IMPase	fusion	proteins	demonstrated	increased	activity	and	possess	a	V-shaped	confirmation.	These	fusion	proteins	may	be	used	to	study	the	protein	complex	further.	In	structural	studies	the	use	of	cryo-EM	may	yield	the	best	results	as	the	flexible	linkers	may	inhibit	crystallisation.		The	fusion	proteins	are	considered	too	large	to	be	useful	for	NMR	studies.	Further	mutagenesis	or	kinetic	studies	of	the	fusion	 proteins	 may	 also	 provide	 more	 insight	 into	 the	 mechanism	 by	 which	Calbindin-D28K	increases	the	activity	of	IMPase.		I	 have	 significantly	 expanded	 the	known	chemical	matter	 that	both	binds	 to	 and	inhibits	IMPase.	A	novel	fragment	binding	site	at	the	homodimer	interface	of	IMPase	was	identified	and	single	mutations	at	the	site	inhibit	protein	activity	by	over	50%.	However,	 more	 work	 is	 required	 to	 identity	 the	 properties	 of	 the	 homodimer	interface	that	are	critical	for	IMPase	activity.	This	data	would	enable	effective	design	of	 IMPase	 inhibitors	 at	 the	 homodimer	 interface.	 The	 fragments	 identified	 here	would	need	further	development	before	they	would	be	of	therapeutic	interest.	This	could	be	achieved	either	by	the	creation	of	a	PROTAC	that	would	induce	the	in	situ	degradation	 of	 IMPase	 or	 by	 development	 of	 the	 fragments	 into	 a	 homodimer	penetrating	compound.							
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Four	 novel	 irreversible	 inhibitors	 of	 IMPase	were	 identified.	 	 These	 compounds	possess	a	similar	reactive	group	to	the	previously	identified	inhibitor	ebselen	and	likely	inhibit	via	a	similar	mechanism.	All	of	these	compounds	inhibited	IMPase	at	IC50	 concentrations	 close	 to	 that	 of	 ebselen.	 As	 these	 new	 compounds	 were	identified	 from	 a	 small,	 targeted	 screen	 of	 67	 compounds,	 this	 indicates	 that	medicinal	chemistry	efforts	around	this	reactive	group	may	enable	the	development	of	a	high	affinity	and	specific	inhibitor.					 	
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Appendix  
Supplementary	Figure	1		
	
Figure	 S1	 Anomalous	 Fourier	 map	 and	 heavy	 atoms	 computed	 with	 ANODE	 (Thorn	 &	
Sheldrick,	 2011).	 Only	 the	 calcium	 binding	 EF	 hands	 contain	 strong	 peaks	 in	 the	 Fourier	
synthesis,	allowing	the	direct	visualization	of	the	calcium	atoms	from	crystal	condition	1.	EF	
hand	1,	3,	4	and	5	contain	calcium	with	EF1	having	 two	strong	peaks	 indicating	 it	binding	
calcium	in	two	different	conformations.			
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Supplementary	Figure	2		
	
Figure	S2	This	figure	is	colour	coded,	blue	APO	and	pink	for	calcium	bound	Calbindin-	D28K	
A.	Log10	SAXS	intensity	versus	scattering	vector,	q.	Plotted	range	represents	the	positive	only	
data	 within	 the	 specified	 q-range.	 B.	 Pair-distance,	 P(r),	 distribution	 function.	 Maximum	
dimension,	 dmax,	 is	 the	 largest	 non-negative	 value	 that	 supports	 a	 smooth	 distribution	
function.	The	Guinier	fitting	for	both	data	sets	are	also	shown.	C.	Dimensionless	Kratky	plot.	
Cross-hair	marks	the	Guinier-Kratky	point	(1.732,	1.1),	the	main	peak	position	for	globular	
particles.	D.	Ab	initio	envelopes	with	6FIE	superimposed.			
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Supplementary	Figure	3	
	
Figure	S3	 shown	here	 is	 the	electron	density	of	 a	 IMPase	 crystal	 soaked	with	 the	 reactive	
fragment	 UOS-19245,	 4	 different	 cysteine	 residues	 have	 additional	 electron	 density	 that	
suggested	 the	presents	of	 the	 fragment.	 It	 can	be	sheen	 from	the	electron	density	 that	 the	
fragment	is	only	partially	visible	with	cysteine	184	and	218,	and	bound	close	to	full	occupancy	
with	cysteine	8	and	14	
